0000899749-20-000049.txt : 20200506 0000899749-20-000049.hdr.sgml : 20200506 20200506163341 ACCESSION NUMBER: 0000899749-20-000049 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHCARE REALTY TRUST INC CENTRAL INDEX KEY: 0000899749 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 621507028 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11852 FILM NUMBER: 20853115 BUSINESS ADDRESS: STREET 1: 3310 WEST END AVE STREET 2: FOURTH FL SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6152698175 MAIL ADDRESS: STREET 1: 3310 WEST END AVENUE, SUITE 700 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 hr-2020331singlesource.htm 10-Q Document
false--12-31Q120202020-03-31000089974900.300.300.010.013000000003000000001347060001349320001347060001349320000.010.0150000000500000000000 0000899749 2020-01-01 2020-03-31 0000899749 2020-05-01 0000899749 2019-12-31 0000899749 2020-03-31 0000899749 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000899749 hr:CumulativeDividendsMember 2020-03-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000899749 hr:CumulativeDividendsMember 2019-12-31 0000899749 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeNetIncomeMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeDividendsMember 2020-01-01 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000899749 2018-12-31 0000899749 us-gaap:CommonStockMember 2020-03-31 0000899749 2019-03-31 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeDividendsMember 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2019-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 us-gaap:CommonStockMember 2019-03-31 0000899749 hr:MiscellaneousMember 2020-01-01 2020-03-31 0000899749 hr:MiscellaneousMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2020-01-01 2020-03-31 0000899749 hr:ParkingIncomeMember 2020-01-01 2020-03-31 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-03-31 0000899749 hr:RentalLeaseGuarantyMember 2020-01-01 2020-03-31 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-03-31 0000899749 us-gaap:LandMember 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:CA 2020-01-03 2020-01-03 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA 2020-02-13 0000899749 hr:RealEstateAcquisitionsMember 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:ColoradoCityCOMember 2020-03-09 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:ColoradoCityCOMember 2020-03-09 2020-03-09 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-01-01 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:GA 2020-02-13 2020-02-13 0000899749 us-gaap:LandMember 2020-01-01 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:NC 2020-02-25 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:CA 2020-01-03 0000899749 hr:RealEstateAcquisitionsMember 2020-01-01 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember stpr:NC 2020-02-25 2020-02-25 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-03-31 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DenverCOMember 2020-03-09 2020-03-09 0000899749 hr:RealEstateAcquisitionsMember hr:MedicalOfficeBuildingMember hr:DenverCOMember 2020-03-09 0000899749 srt:MaximumMember 2020-03-31 0000899749 srt:MinimumMember 2020-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2020-03-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2020-03-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-03-04 0000899749 us-gaap:MortgagesMember 2020-02-03 0000899749 us-gaap:MortgagesMember 2020-02-03 2020-02-03 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-01-01 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-03-04 2020-03-04 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-02-25 0000899749 hr:ActiveInterestRateSwapsMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-02-24 0000899749 us-gaap:TreasuryLockMember 2020-03-04 2020-03-04 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateContractMember 2020-01-01 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:MemphisTennesseeMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:MemphisTennesseeMember us-gaap:LandAndBuildingMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingExpansionMember hr:MemphisTennesseeMember 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2019-12-31 0000899749 hr:StockIncentivePlanMember 2020-01-01 2020-03-31 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2019-12-31 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 hr:StockIncentivePlanMember 2020-03-31 0000899749 hr:StockIncentivePlanMember 2019-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MinimumMember 2020-01-01 2020-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2020-01-01 2020-03-31 0000899749 us-gaap:SubsequentEventMember 2020-05-06 0000899749 hr:AtTheMarketEquityOfferingProgramMember srt:MaximumMember 2020-01-01 2020-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember us-gaap:SubsequentEventMember 2020-03-18 2020-05-06 0000899749 2020-02-14 0000899749 us-gaap:SubsequentEventMember 2020-05-29 2020-05-29 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000899749 us-gaap:SubsequentEventMember 2020-04-01 2020-05-04 0000899749 us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 hr:Lease iso4217:USD xbrli:shares hr:derivative xbrli:shares hr:swap_agreement hr:treasury_lock iso4217:USD utreg:sqft hr:state hr:property xbrli:pure

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2020

OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period             to

For the transition period             to

Commission File Number: 001-11852

HEALTHCARE REALTY TRUST INCORPORATED
(Exact name of Registrant as specified in its charter) 
Maryland
62-1507028
(State or other jurisdiction of
Incorporation or organization)
(I.R.S. Employer
Identification No.)
3310 West End Avenue, Suite 700
Nashville, Tennessee 37203
(Address of principal executive offices)
(615) 269-8175
(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
 
Trading Symbol
 
Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share
 
HR
 
New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large accelerated filer         Accelerated filer         
Non-accelerated filer         Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      No  ☒
 
As of May 1, 2020, the Registrant had 134,932,261 shares of Common Stock outstanding.



 


HEALTHCARE REALTY TRUST INCORPORATED
FORM 10-Q
March 31, 2020


Table of Contents



PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Healthcare Realty Trust Incorporated
Condensed Consolidated Balance Sheets
Amounts in thousands, except per share data

ASSETS
 
 
 
Unaudited
MARCH 31, 2020

DECEMBER 31, 2019

Real estate properties
 
 
Land
$
319,882

$
289,751

Buildings, improvements and lease intangibles
4,126,046

3,986,326

Personal property
10,783

10,538

Construction in progress

48,731

Land held for development
24,647

24,647

Total real estate properties
4,481,358

4,359,993

Less accumulated depreciation and amortization
(1,164,462
)
(1,121,102
)
Total real estate properties, net
3,316,896

3,238,891

Cash and cash equivalents
103,370

657

Assets held for sale, net
20

37

Operating lease right-of-use assets
125,040

126,177

Financing lease right-of-use assets
12,615

12,667

Other assets, net
189,708

185,426

Total assets
$
3,747,649

$
3,563,855

 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
Liabilities
 
 
Notes and bonds payable
$
1,644,454

$
1,414,069

Accounts payable and accrued liabilities
64,574

78,517

Liabilities of properties held for sale
74

145

Operating lease liabilities
91,093

91,574

Financing lease liabilities
17,953

18,037

Other liabilities
70,073

61,504

Total liabilities
1,888,221

1,663,846

Commitments and contingencies




Stockholders' equity
 
 
Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding


Common stock, $.01 par value per share; 300,000 shares authorized; 134,932 and 134,706 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
1,349

1,347

Additional paid-in capital
3,494,123

3,485,003

Accumulated other comprehensive loss
(19,777
)
(6,175
)
Cumulative net income attributable to common stockholders
1,131,619

1,127,304

Cumulative dividends
(2,747,886
)
(2,707,470
)
Total stockholders' equity
1,859,428

1,900,009

Total liabilities and stockholders' equity
$
3,747,649

$
3,563,855

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.



1



Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Income
For the Three Months Ended March 31, 2020 and 2019
Amounts in thousands, except per share data
Unaudited

 
THREE MONTHS ENDED
March 31,
 
2020

2019

Revenues
 
 
Rental income
$
122,644

$
110,696

Other operating
2,163

1,961

 
124,807

112,657

Expenses
 
 
Property operating
49,552

42,725

General and administrative
8,766

8,510

Acquisition and pursuit costs
750

305

Depreciation and amortization
47,497

42,662

 
106,565

94,202

Other Income (Expense)
 
 
Gain (loss) on sales of real estate assets
(49
)
15

Interest expense
(13,960
)
(13,588
)
Interest and other income (expense), net
82

9

 
(13,927
)
(13,564
)
Net Income
$
4,315

$
4,891

 
 
 
Basic earnings per common share
$
0.03

$
0.04

Diluted earnings per common share
$
0.03

$
0.04

 
 
 
Weighted average common shares
outstanding - basic
133,036

124,130

Weighted average common shares
outstanding - diluted
133,150

124,232

Dividends declared, per common share,
during the period
$
0.30

$
0.30

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.



2



Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Comprehensive Income
For the Three Months Ended March 31, 2020 and 2019
Amounts in thousands
Unaudited

 
THREE MONTHS ENDED
March 31,
 
2020

2019

Net income
$
4,315

$
4,891

Other comprehensive income (loss)
 
 
Interest rate swaps
 
 
Reclassification adjustments for losses included in net income (interest expense)
328

15

Losses arising during the period on interest rate swaps
(9,663
)
(724
)
Losses on settlement of treasury rate locks arising during the period
(4,267
)

 
(13,602
)
(709
)
Comprehensive income
$
(9,287
)
$
4,182

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.



3



Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Equity
For the Three Months Ended March 31, 2020 and 2019
Amounts in thousands, except per share data
Unaudited

 
Common
Stock

Additional
Paid-In
Capital

Accumulated
Other
Comprehensive
Income (Loss)

Cumulative
Net Income

Cumulative
Dividends

Total
Stockholders’
Equity

Balance at December 31, 2019
$
1,347

$
3,485,003

$
(6,175
)
$
1,127,304

$
(2,707,470
)
$
1,900,009

Issuance of common stock, net of
issuance costs
2

7,319




7,321

Common stock redemptions

(798
)



(798
)
Share-based compensation

2,599




2,599

Net income



4,315


4,315

Reclassification adjustments for losses included in net income (interest expense)



328



328

Losses arising during the period on
treasury rate locks



(13,930
)


(13,930
)
Dividends to common stockholders
($0.30 per share)




(40,416
)
(40,416
)
Balance at March 31, 2020
$
1,349

$
3,494,123

$
(19,777
)
$
1,131,619

$
(2,747,886
)
$
1,859,428

 
 
 
 
 
 
 
 
Common
Stock

Additional
Paid-In
Capital

Accumulated
Other
Comprehensive
Income (Loss)

Cumulative
Net Income

Cumulative
Dividends

Total
Stockholders’
Equity

Balance at December 31, 2018
$
1,253

$
3,180,284

$
(902
)
$
1,088,119

$
(2,552,112
)
$
1,716,642

Issuance of common stock, net of issuance costs
38

120,462




120,500

Common stock redemptions

(570
)



(570
)
Share-based compensation
1

2,638




2,639

Net income



4,891


4,891

Reclassification adjustments for losses included in net income (interest expense)



15



15

Losses arising during the period on interest rate swaps



(724
)


(724
)
Dividends to common stockholders ($0.30 per share)




(37,614
)
(37,614
)
Balance at March 31, 2019
$
1,292

$
3,302,814

$
(1,611
)
$
1,093,010

$
(2,589,726
)
$
1,805,779

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.





4



Healthcare Realty Trust Incorporated
Condensed Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2020 and 2019
Amounts in thousands
Unaudited

OPERATING ACTIVITIES
 
 
 
THREE MONTHS ENDED
 March 31,
 
2020

2019

Net income
$
4,315

$
4,891

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
Depreciation and amortization
47,497

42,662

Other amortization
1,491

727

Share-based compensation
2,599

2,639

Amortization of straight-line rent receivable (lessor)
(1,043
)
(668
)
Amortization of straight-line rent on operating leases (lessee)
375

390

(Gain) loss on sales of real estate assets
49

(15
)
Loss from unconsolidated joint ventures
11

10

Distributions from unconsolidated joint ventures
118

88

Changes in operating assets and liabilities:
 
 
Other assets, including right-of-use-assets
(4,032
)
(4,971
)
Accounts payable and accrued liabilities
(10,005
)
(10,276
)
Other liabilities
(2,931
)
(673
)
Net cash provided by operating activities
38,444

34,804

 
 
 
INVESTING ACTIVITIES
 
 
Acquisitions of real estate
(83,580
)
(91,787
)
Development of real estate
(2,451
)
(5,712
)
Additional long-lived assets
(22,164
)
(11,741
)
Net cash used in investing activities
(108,195
)
(109,240
)
 
 
 
FINANCING ACTIVITIES
 
 
Net repayments on unsecured credit facility
(78,000
)
(2,000
)
Borrowings of notes and bonds payable
298,995


Repayments of notes and bonds payable
(7,202
)
(1,193
)
Dividends paid
(40,416
)
(37,614
)
Net proceeds from issuance of common stock
7,213

120,617

Common stock redemptions
(892
)
(2,442
)
Settlement of treasury rate locks
(4,267
)

Debt issuance and assumption costs
(2,646
)

Payments made on finance leases
(321
)

Net cash provided by financing activities
$
172,464

$
77,368

 
 
 
Increase in cash and cash equivalents
102,713

2,932

Cash and cash equivalents at beginning of period
657

8,381

Cash and cash equivalents at end of period
$
103,370

$
11,313

 
 
 
Supplemental Cash Flow Information
 
 
Interest paid
$
11,428

$
11,071

Invoices accrued for construction, tenant improvements and other capitalized costs
$
12,830

$
13,509

Mortgage notes payable assumed upon acquisition (adjusted to fair value)
$
19,269

$

Capitalized interest
$
421

$
307

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are an integral part of these financial statements.



5



NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


Note 1. Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2020, the Company had gross investments of approximately $4.4 billion in 212 real estate properties located in 25 states totaling approximately 15.8 million square feet. The Company provided leasing and property management services to approximately 12.0 million square feet nationwide. Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.
The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at March 31, 2020. A prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company.
This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.



6



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
 
THREE MONTHS ENDED
March 31,
in thousands
2020

2019

Type of Revenue
 
 
Parking income
$
2,051

$
1,734

Rental lease guaranty

128

Management fee income
78

69

Miscellaneous
34

30

 
$
2,163

$
1,961


The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements
Accounting Standards Update No. 2016-13
In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2020-04
On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.



7



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Note 2. Real Estate Investments
2020 Acquisitions
The following table details the Company's acquisitions for the three months ended March 31, 2020:
Dollars in millions
TYPE 1
DATE ACQUIRED
PURCHASE PRICE

MORTGAGE NOTES PAYABLE

CASH
CONSIDERATION
2

REAL
ESTATE

OTHER 3

SQUARE FOOTAGE

Los Angeles, CA
MOB
1/3/20
$
42.0

$
(19.3
)
$
22.8

$
42.4

$
(0.3
)
86,986

Atlanta, GA
MOB
2/13/20
12.0


11.8

12.1

(0.3
)
64,624

Raleigh, NC
MOB
2/25/20
6.3


6.5

6.5


15,964

Colorado Springs, CO
MOB
3/9/20
8.2


8.3

8.6

(0.3
)
34,210

Denver, CO 4
MOB
3/13/20
33.5


33.2

34.0

(0.8
)
136,994

Total real estate acquisitions
 
$
102.0

$
(19.3
)
$
82.6

$
103.6

$
(1.7
)
338,778

Land acquisition 5
 
 
1.6


1.7

1.7



 
 
 
$
103.6

$
(19.3
)
$
84.3

$
105.3

$
(1.7
)
338,778

1
MOB = medical office building.
2
Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
3
Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
4
Includes three properties.
5
The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system).

Assets Held for Sale
As of March 31, 2020 and December 31, 2019, the Company had no properties classified as held for sale.
Note 3. Leases
Lessor Accounting
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2020 was $122.6 million.
Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2020 were as follows:
In thousands
 
2020
$
280,413

2021
335,188

2022
294,771

2023
250,284

2024
193,772

2025 and thereafter
514,144

 
$
1,868,572





8



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.



Lessee Accounting
As of March 31, 2020, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2020, the Company had 104 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of March 31, 2020. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended March 31, 2020 and March 31, 2019, respectively.
The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of March 31, 2020 were as follows:
In thousands
OPERATING

FINANCING

2020
$
3,113

$
429

2021
4,844

754

2022
4,875

763

2023
4,913

774

2024
4,969

795

2025 and thereafter
307,665

83,404

Total undiscounted lease payments
330,379

86,919

Discount
(239,286
)
(68,966
)
Lease liabilities
$
91,093

$
17,953






9



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


The following table provides details of the Company's total lease expense for the three months ended March 31, 2020 and 2019:
 
THREE MONTHS ENDED MARCH 31,
In thousands
2020

2019

Operating lease cost
 
 
Operating lease expense
$
1,174

$
1,116

Variable lease expense
800

740

 
 
 
Finance lease cost
 
 
Amortization of right-of-use assets
70


Interest on lease liabilities
237


Total lease expense
$
2,281

$
1,856

 
 
 
Other information
 
 
Operating cash flows outflows related to operating leases
$
2,550

$
2,771

Financing cash flows outflows related to financing leases
$
321

$

Right-of-use assets obtained in exchange for new finance lease liabilities
$

$

 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
49.4

54.0

Weighted-average remaining lease term (excluding renewal options) -finance leases
64.9


Weighted-average discount rate - operating leases
5.7
%
5.5
%
Weighted-average discount rate - finance leases
5.4
%
%





10



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Note 4. Notes and Bonds Payable
The table below details the Company’s notes and bonds payable. 
 
MATURITY DATES
BALANCE AS OF
EFFECTIVE INTEREST RATE
as of 3/31/2020

Dollars in thousands
3/31/2020

12/31/2019

$700 million Unsecured Credit Facility
5/23
$
215,000

$
293,000

1.89
%
$200 million Unsecured Term Loan Facility, net of issuance costs 1
5/24
199,069

199,013

3.20
%
$150 million Unsecured Term Loan due 2026 2
6/26


N/A

Senior Notes due 2023, net of discount and issuance costs
4/23
248,647

248,540

3.95
%
Senior Notes due 2025, net of discount and issuance costs 3
5/25
248,584

248,522

4.08
%
Senior Notes due 2028, net of discount and issuance costs
1/28
295,768

295,651

3.84
%
Senior Notes due 2030, net of discount and issuance costs 4
3/30
296,211


2.71
%
Mortgage notes payable, net of discounts and issuance costs and including premiums
7/20-5/40
141,175

129,343

4.70
%
 
 
$
1,644,454

$
1,414,069

 

1
The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
2
As of March 31, 2020, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until May 29, 2020 to draw against the commitments.
3
The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.
4
The effective interest rate includes the impact of the $4.3 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

Changes in Debt Structure
On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.
On March 4, 2020, the Company issued $300.0 million of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.
Note 5. Derivative Financial Instruments
Risk Management Objective of Using Derivatives
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.




11



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Cash Flow Hedges of Interest Rate Risk
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.
For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.
On February 24 and 25, 2020, the Company entered into two treasury rate locks totaling $75.0 million and $40.0 million, respectively. The treasury rate locks were settled for an aggregate amount of $4.3 million on March 4, 2020 concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10-year term of the notes.
As of March 31, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
DERIVATIVE INSTRUMENT
NUMBER OF INSTRUMENTS

NOTIONAL AMOUNT
in millions
Interest rate swaps
8

$175.0


Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2020.
 
BALANCE AT MARCH 31, 2020
In thousands
BALANCE SHEET LOCATION
FAIR VALUE

Derivatives designated as hedging instruments
 
 
Interest rate swaps
Other liabilities
$
14,672

Total derivatives designated as hedging instruments
 
$
14,672



Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2020 and 2019 related to the Company's outstanding interest rate swaps.
 
LOSS RECOGNIZED IN
AOCI ON DERIVATIVE
three months ended March 31,
 
(GAIN) LOSS RECLASSIFIED FROM
AOCI INTO INCOME
three months ended March 31,
In thousands
2020

2019

2020

2019

Interest rate swaps
$
9,663

$
724

Interest expense
$
271

$
(27
)
Settled treasury hedges
4,267


Interest expense
15


Settled interest rate swaps


Interest expense
42

42

 
$
13,930

$
724

Total interest expense
$
328

$
15

The Company estimates that $4.0 million will be reclassified from AOCI to interest expense over the next 12 months.
Credit-risk-related Contingent Features
The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.



12



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


As of March 31, 2020, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $15.2 million. As of March 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement.
Note 6. Commitments and Contingencies
Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Redevelopment Activity
The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. The Company funded approximately $1.5 million, excluding the purchase price of $8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The Memphis Redevelopment is expected to be completed in the first quarter of 2021.

Development Activity
The Company completed the development of a 151,031 square foot medical office building in Seattle, Washington. As of March 31, 2020, the Company had funded approximately $54.1 million towards the development. The Company expects to fund an additional amount of approximately $10.0 million for additional tenant improvements associated with this project. The first tenant took occupancy in the first quarter of 2020.
Note 7. Stockholders' Equity
Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2020 and the year ended December 31, 2019:
 
MARCH 31, 2020

DECEMBER 31, 2019

Balance, beginning of period
134,706,154

125,279,455

Issuance of common stock
210,271

9,251,440

Nonvested share-based awards, net of withheld shares
15,781

175,259

Balance, end of period
134,932,206

134,706,154



At-The-Market Equity Offering Program
On February 14, 2020, the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. During the first quarter of 2020, the Company sold 196,250 shares under the Company's at-the-market equity offering program generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share). No shares were sold from March 18, 2020 through the date of this filing. The Company had $492.9 million remaining available to be sold under the current sales agreements at the date of this filing.

Common Stock Dividends
During the three months ended March 31, 2020, the Company declared and paid common stock dividends totaling $0.30 per share. On May 5, 2020, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on May 29, 2020 to stockholders of record on May 15, 2020.



13



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2020 and 2019.
 
THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data
2020

2019

Weighted average common shares outstanding
 
 
Weighted average common shares outstanding
134,758,335

125,908,335

Non-vested shares
(1,722,090
)
(1,778,700
)
Weighted average common shares outstanding - basic
133,036,245

124,129,635

 
 
 
Weighted average common shares outstanding - basic
133,036,245

124,129,635

Dilutive effect of employee stock purchase plan
113,321

102,132

Weighted average common shares outstanding - diluted
133,149,566

124,231,767

 
 
 
Net Income
$
4,315

$
4,891

Dividends paid on nonvested share-based awards
(517
)
(536
)
Net income applicable to common stockholders
$
3,798

$
4,355

 
 
 
Basic earnings per common share - net income
$
0.03

$
0.04

Diluted earnings per common share - net income
$
0.03

$
0.04



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2020 and 2019 is included in the table below.
 
THREE MONTHS ENDED MARCH 31,
 
2020

2019

Share-based awards, beginning of period
1,754,066

1,769,863

Granted
39,344

64,771

Vested
(68,649
)
(50,507
)
Share-based awards, end of period
1,724,761

1,784,127


During the three months ended March 31, 2020 and 2019, the Company withheld 23,563 and 19,546 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.
In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three months ended March 31, 2020 and 2019 is included in the table below.
 
THREE MONTHS ENDED MARCH 31,
 
2020

2019

Outstanding and exercisable, beginning of period
332,659

328,533

Granted
212,716

235,572

Exercised
(11,904
)
(14,630
)
Forfeited
(22,981
)
(16,625
)
Expired
(139,794
)
(142,074
)
Outstanding and exercisable, end of period
370,696

390,776





14



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Note 8. Fair Value of Financial Instruments
The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.
Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.
Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.
Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.
Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.
The table below details the fair values and carrying values for notes and bonds payable at March 31, 2020 and December 31, 2019.
 
MARCH 31, 2020
DECEMBER 31, 2019
Dollars in millions
CARRYING VALUE

FAIR VALUE

CARRYING VALUE

FAIR VALUE

Notes and bonds payable 1
$
1,644.5

$
1,706.7

$
1,414.1

$
1,425.8


1
Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.



15



NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS, cont.


Note 9. Subsequent Events
COVID-19 Update
Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.
All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects have instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants have temporarily closed their offices or clinical space or have operated on a reduced basis in response to government requirements or recommendations. Through May 5, 2020, the Company has collected 89% of April 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 7% of April 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. However, if tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants, including the Coronavirus Aid, Relief, and Economic Security Act or the “CARES Act".
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Disclosure Regarding Forward-Looking Statements
This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are “forward-looking statements.” Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “target,” “intend,” “plan,” “estimate,” “project,” “continue,” “should,” “could," "budget" and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including  the duration and scope of the COVID-19 pandemic; the impact of the COVID-19 pandemic on occupancy rates for the Company's properties, actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting the Company’s properties and the operations of the Company and its tenants; the effects of health and safety measures adopted by the Company and its tenants related to the COVID-19 pandemic; the impact of the COVID-19 pandemic on the operations, business and financial condition of the Company and its tenants; general economic uncertainty in key markets as a result of the COVID-19 pandemic and a worsening of global economic conditions or low levels of economic growth; the status of capital markets, including availability and cost of capital; and the risks described in this report and the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, that could significantly affect the Company’s current plans and expectations and future financial condition and results.
The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company’s filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.
For a detailed discussion of the Company’s risk factors, please refer to the Company’s filings with the Securities and Exchange Commission, including this report and its Annual Report on Form 10-K for the year ended December 31, 2019.

COVID-19 Update
Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.



16



All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects have instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants have temporarily closed their offices or clinical space or have operated on a reduced basis in response to government requirements or recommendations. Through May 5, 2020, the Company has collected 89% of April 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 7% of April 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. The tenant deferral agreements require the amounts to be repaid in the third and fourth quarters of 2020. Many of these tenants have requested, and the Company management expects more will likely seek, rent deferral or abatement for May 2020 and subsequent months, though it cannot predict how many.
Management believes that many of its tenants who have experienced disruption to their businesses as a result of the COVID-19 pandemic will qualify for various forms of government financial assistance including pursuant to the CARES Act, which was signed into law on March 27, 2020. Accordingly, the Company has undertaken efforts to promote awareness of the availability of these initiatives to its tenants. At this time, the Company expects to collect the deferred rent prior to the end of 2020. However, if tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads (See “Expiring Leases” below), the impact on the Company’s results of operations and financial condition could be material. As a result, the Company cannot estimate at this time the overall effect that the COVID-19 pandemic might have on its business.
At March 31, 2020, the Company had available $738.4 million in liquidity (See “Sources and Uses of Cash” and “Financing Activities” below) and no significant debt maturities prior to 2023. The COVID-19 pandemic has affected the availability and cost of capital and may continue to do so for some time. Management believes that the Company currently has adequate liquidity to operate its business without significant disruption. However, if the pandemic continues to have an impact on the availability and cost of capital, the Company’s business could be materially affected.
Liquidity and Capital Resources
Sources and Uses of Cash
The Company’s primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants, borrowings under the Company's Unsecured Credit Facility and Term Loan, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings. As of March 31, 2020, the Company had $485.0 million available to be drawn on its Unsecured Credit Facility, $103.4 million in cash, and has the ability to draw $150.0 million on its unsecured term loan due 2026.
The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service, through cash flows from operations and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately $4.1 billion at March 31, 2020, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.
Dividends paid by the Company for the three months ended March 31, 2020 were funded from cash flows from operations and the Unsecured Credit Facility, as cash flows from operations were not adequate to fully fund dividends paid at the rate per quarter of $0.30 per common share. The Company expects that additional cash flows from existing properties, acquisitions and developments will generate sufficient cash flows from operations such that dividends for the full year 2020 can be funded by cash flows from operations or other sources of liquidity described above.




17



Investing Activities
Cash flows used in investing activities for the three months ended March 31, 2020 were approximately $108.2 million. Below is a summary of significant investing activities.
2020 Acquisitions
The following table details the Company's acquisitions for the three months ended March 31, 2020:
Dollars in millions
HEALTH SYSTEM AFFILIATION
DATE ACQUIRED
PURCHASE PRICE

SQUARE FOOTAGE

CAP
RATE

MILES TO CAMPUS

Los Angeles, CA
MemorialCare Health
1/3/20
$
42.0

86,986

5.3
%
0.14

Atlanta, GA
Wellstar Health System
2/13/20
12.0

64,624

5.6
%
0.10

Raleigh, NC
WakeMed Health
2/25/20
6.3

15,964

6.7
%
0.04

Colorado Springs, CO
None
3/9/20
8.2

34,210

6.5
%
1.60

Denver, CO 1
UCHealth
3/13/20
33.5

136,994

6.1
%
0.24

Total real estate acquisitions
 
 
$
102.0

338,778

5.8
%
 
Land acquisition 2
 
 
1.6


 
 
 
 
 
$
103.6

338,778

 
 
1
Includes three properties.
2
The Company acquired land parcels under four existing buildings (previously ground leased with the hospital system).

Capital Funding
During the three months ended March 31, 2020, the Company funded the following:
$6.9 million toward development and redevelopment of properties;
$2.7 million toward first generation tenant improvements and planned capital expenditures for acquisitions;
$6.0 million toward second generation tenant improvements; and
$3.5 million toward capital expenditures.

Financing Activities
Cash flows provided by financing activities for the three months ended March 31, 2020 were approximately $172.5 million. Inflows from equity related to the Company's common stock issuances and net borrowings totaled $306.2 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately $133.7 million primarily associated with dividends paid to common stockholders and repayments on the Credit Facility. See Notes 4 and 7 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Common Stock Issuances
On February 14, 2020, the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. During the first quarter of 2020, the Company sold 196,250 shares under the Company's at-the-market equity offering program generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share). No shares were sold from March 18, 2020 through the date of this filing. The Company had $492.9 million remaining available to be sold under the current sales agreements at the date of this filing.

Debt Activity
On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.



18



On March 4, 2020, the Company issued $300.0 million of the Senior Notes due 2030 in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.
The Company has outstanding interest rate swaps totaling $175.0 million to hedge one-month LIBOR. The following details the amount and rate of each swap (dollars in thousands):
EFFECTIVE DATE
AMOUNT

WEIGHTED
AVERAGE RATE

EXPIRATION DATE
December 18, 2017
$
25,000

2.18
%
December 16, 2022
February 1, 2018
50,000

2.46
%
December 16, 2022
May 1, 2019
50,000

2.33
%
May 1, 2026
June 3, 2019
50,000

2.13
%
May 1, 2026
 
$
175,000

2.29
%
 

Operating Activities
Cash flows provided by operating activities increased from $34.8 million for the three months ended March 31, 2019 to $38.4 million for the three months ended March 31, 2020. Items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses.
The Company may, from time to time, sell properties and redeploy cash from property sales into new investments. To the extent revenues related to the properties being sold exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements
See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.



19



Trends and Matters Impacting Operating Results
Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, below are some of the factors and trends that management believes may impact future operations of the Company.
COVID-19 Pandemic
For information on the ways that the COVID-19 pandemic is impacting the Company and its tenants, see "COVID-19 Update" above and in Part II, Item 1A.
Expiring Leases
The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 583 leases totaling 2.1 million square feet in the Company's multi-tenant portfolio that will expire during the remainder of 2020. Approximately 85% of the leases expiring in 2020 are in buildings located on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first three months of the year has been within this range.
Included in the 2020 lease expirations is a 111,000 square foot fitness center leased by Baylor Scott & White Health. The fitness center is located in a 217,000 square foot on-campus medical office building. The lease expired on March 31, 2020, and the tenant is currently under a month-to-month lease arrangement as the Company finalizes a new lease with an independent fitness center operator for approximately half the space. The Company expects to redevelop the remaining space for clinical use.
Also included in the 2020 lease expirations is the July 31 expiration of a 62,000 square foot office lease. A telecommunication company occupies three floors of a 145,000 square foot office building and is expected to vacate. The Company has begun marketing the space and anticipates that releasing efforts will include subdividing the space for multiple users. The Company recognized revenue of approximately $0.4 million related to this lease in the first quarter of 2020.
The Company has one single-tenant net leased, on-campus medical office building with a lease term scheduled to expire in the second quarter of 2020. The Company has been in discussions about a long-term lease renewal, but given the COVID-19 pandemic, plans to provide a 6-month extension to allow more time to finalize a long-term lease agreement.

Operating Expenses
The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of March 31, 2020, leases for 89% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 31% having modified gross lease structures and 58% having net lease structures.



20




Purchase Options
Information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):
 
NUMBER OF PROPERTIES
GROSS REAL ESTATE INVESTMENT AS OF MARCH 31, 2020
YEAR EXERCISABLE
MOB

INPATIENT

FAIR MARKET
VALUE METHOD 1

NON FAIR MARKET
VALUE METHOD 2

TOTAL

Current 3
3

1

$
96,233

$

$
96,233

2021
1



14,984

14,984

2022





2023





2024





2025
5

1

48,165

221,929

270,094

2026





2027





2028
1


43,943


43,943

2029
1


26,494


26,494

2030 and thereafter
4


100,151


100,151

Total
15

2

$
314,986

$
236,913

$
551,899

1
The purchase option price includes a fair market value component that is determined by an appraisal process.
2
Includes properties with stated purchase prices or prices based on fixed capitalization rates. These properties have purchase prices that are on average 17% greater than the Company's current gross investment.
3
These purchase options have been exercisable for an average of 11.6 years.

Non-GAAP Financial Measures and Key Performance Indicators
Management considers certain non-GAAP financial measures and key performance indicators to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.
The non-GAAP financial measures and key performance indicators presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Quarterly Report on Form 10-Q.

Funds from Operations ("FFO"), Normalized FFO and Funds Available for Distribution ("FAD")
FFO and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT’s operating performance equal to “net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization, impairment, and after adjustments for unconsolidated partnerships and joint ventures.”
In addition to FFO, the Company presents Normalized FFO and FAD. Normalized FFO is presented by adding to FFO acquisition-related costs, acceleration of debt issuance costs, debt extinguishment costs and other Company-



21



defined normalizing items to evaluate operating performance. FAD is presented by adding to Normalized FFO non-real estate depreciation and amortization, deferred financing fees amortization, stock-based compensation expense and provision for bad debts, net; and subtracting maintenance capital expenditures, including second generation tenant improvements and leasing commissions paid and straight-line rent income, net of expense. The Company's definition of these terms may not be comparable to that of other real estate companies as they may have different methodologies for computing these amounts. Normalized FFO and FAD should not be considered as an alternative to net income as an indicator of the Company's financial performance or to cash flow from operating activities as an indicator of the Company's liquidity. Normalized FFO and FAD should be reviewed in connection with GAAP financial measures.
Management believes FFO, Normalized FFO, FFO per share, Normalized FFO per share and FAD ("Non-GAAP Measures") provide an understanding of the operating performance of the Company’s properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization, impairments and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, Non-GAAP Measures can facilitate comparisons of operating performance between periods. The Company reports Non-GAAP Measures because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these Non-GAAP Measures. However, none of these measures represent cash generated from operating activities determined in accordance with GAAP and are not necessarily indicative of cash available to fund cash needs. Further, these measures should not be considered as an alternative to net income as an indicator of the Company’s operating performance or as an alternative to cash flow from operating activities as a measure of liquidity. The table below reconciles net income to FFO, Normalized FFO and FAD for the three months ended March 31, 2020 and 2019.
 
THREE MONTHS ENDED MARCH 31,
Amounts in thousands, except per share data
2020

2019

Net income
$
4,315

$
4,891

(Gain) loss on sales of real estate assets
49

(15
)
Real estate depreciation and amortization
48,611

43,383

FFO attributable to common stockholders
$
52,975

$
48,259

Acquisition and pursuit costs 1
750

305

Lease intangible amortization
745

84

Normalized FFO attributable to common stockholders
$
54,470

$
48,648

Non-real estate depreciation and amortization
823

763

Non-cash interest expense amortization 2
746

702

Provision for bad debt, net
(83
)
(75
)
Straight-line rent, net
(660
)
(270
)
Stock-based compensation
2,599

2,639

Normalized FFO adjusted for non-cash items
$
57,895

$
52,407

2nd generation TI
(6,040
)
(4,326
)
Leasing commissions paid
(2,824
)
(1,347
)
Capital additions
(3,470
)
(3,462
)
FAD
$
45,561

$
43,272

FFO per common share - diluted
$
0.40

$
0.39

Normalized FFO per common share - diluted
$
0.41

$
0.39

FFO weighted average common shares outstanding - diluted 3
133,980

124,928

1
Acquisition and pursuit costs include third party and travel costs related to the pursuit of acquisitions and developments.
2
Includes the amortization of deferred financing costs, discounts and premiums.
3
The Company utilizes the treasury stock method which includes the dilutive effect of nonvested share-based awards outstanding of 830,024 and 696,432, respectively, for the three months ended March 31, 2020 and 2019.



22




Cash NOI and Same Store Cash NOI
Cash NOI and Same Store Cash NOI are key performance indicators. Management considers these to be supplemental measures that allow investors, analysts and Company management to measure unlevered property-level operating results. The Company defines Cash NOI as rental income and property lease guaranty income less property operating expenses. Cash NOI excludes non-cash items such as above and below market lease intangibles, straight-line rent, lease inducements, tenant improvement amortization and leasing commission amortization. The Company also excludes cash lease termination fees. Cash NOI is historical and not necessarily indicative of future results.
Same Store Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented and include redevelopment projects. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, reposition properties and newly developed properties. The Company utilizes the reposition classification for properties experiencing a shift in strategic direction. Such a shift can occur for a variety of reasons, including a substantial change in the use of the asset, a change in strategy or closure of a neighboring hospital, or significant property damage. Such properties may require enhanced management, leasing, capital needs or a disposition strategy that differs from the rest of the portfolio. To identify properties exhibiting these reposition characteristics, the Company applies the following Company-defined criteria:
Properties having less than 60% occupancy that is expected to last at least two quarters;
Properties that experience a loss of occupancy over 30% in a single quarter; or
Properties with negative net operating income that is expected to last at least two quarters.



23



Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Newly developed properties will be included in the same store pool eight full quarters after substantial completion. Any additional square footage created by redevelopment projects at a same store property is included in the same store pool immediately upon completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters. The following table reflects the Company's same store cash NOI for the three months ended March 31, 2020 and 2019.
 
NUMBER OF PROPERTIES

GROSS INVESTMENT
at March 31, 2020

SAME STORE CASH NOI for the three months ended March 31,
Dollars in thousands
2020

2019

Multi-tenant properties
157

$
3,248,042

$
57,981

$
56,751

Single-tenant net lease properties
14

460,433

10,449

10,271

Total
171

$
3,708,475

$
68,430

$
67,022

The following tables reconcile net income to same store NOI and the same store property metrics to the total owned real estate portfolio for the three months ended March 31, 2020 and 2019:

Reconciliation of Same Store Cash NOI
 
THREE MONTHS ENDED MARCH 31,
Dollars in thousands
2020

2019

Net income
$
4,315

$
4,891

Other income (expense)
13,927

13,564

General and administrative expense
8,766

8,510

Depreciation and amortization expense
47,497

42,662

Other expenses 1
3,365

1,768

Straight-line rent revenue
(668
)
(277
)
Other revenue 2
(2,004
)
(1,468
)
Cash NOI
75,198

69,650

Cash NOI not included in same store
(6,529
)
(2,361
)
Same store cash NOI
68,669

67,289

Reposition NOI
(239
)
(267
)
Same store and reposition cash NOI
$
68,430

$
67,022

1
Includes acquisition and pursuit costs, bad debt, above and below market ground lease intangible amortization, leasing commission amortization and ground lease straight-line rent expense.
2
Includes management fee income, interest, above and below market lease intangible amortization, lease inducement amortization, lease terminations and tenant improvement overage amortization.

Reconciliation of Same Store Properties
 
AS OF MARCH 31, 2020
 
PROPERTY COUNT

GROSS INVESTMENT

SQUARE
FEET

OCCUPANCY

Same store properties
171

$
3,708,475

13,439,999

89.0
%
Acquisitions
31

606,061

1,826,029

86.9
%
Development completions
1

53,669

151,031

20.2
%
Reposition
9

72,782

429,167

41.9
%
Total owned real estate properties
212

$
4,440,987

15,846,226

86.8
%
Results of Operations
Three Months Ended March 31, 2020 Compared to Three Months Ended March 31, 2019
The Company’s results of operations for the three months ended March 31, 2020 compared to the same period in 2019 were impacted by acquisitions, developments, dispositions, gains on sale, and capital markets transactions.



24



Revenues
Total revenues increased $12.2 million, or 10.8%, to approximately $124.8 million for the three months ended March 31, 2020 compared to $112.7 million in the prior year period. This increase is comprised of the following:
 
THREE MONTHS ENDED MARCH 31,
CHANGE
Dollars in thousands
2020

2019

$

%

Property operating
$
111,148

$
98,982

$
12,166

12.3
 %
Single-tenant net lease
10,453

11,046

(593
)
(5.4
)%
Straight-line rent
1,043

668

375

56.1
 %
Rental income
122,644

110,696

11,948

10.8
 %
Other operating
2,163

1,961

202

10.3
 %
Total revenues
$
124,807

$
112,657

$
12,150

10.8
 %
Property operating revenue increased $12.2 million, or 12.3%, from the prior year period primarily as a result of the following activity:
Acquisitions in 2019 and 2020 and a development in 2020 contributed $9.4 million.
Leasing activity, including contractual rent increases, contributed $3.8 million.
Dispositions in 2019 resulted in a decrease of $1.0 million.
Single-tenant net lease revenue decreased $0.6 million, or 5.4%, from the prior year period primarily as a result of the following activity:
Dispositions in 2019 resulted in a decrease of $0.8 million.
Leasing activity, including contractual rent increases, contributed $0.2 million.
Straight-line rent revenue increased $0.4 million or 56.1% from the prior year primarily due to acquisitions in 2019 and 2020 and a development in 2020.

Expenses
Property operating expenses increased $6.8 million, or 16.0%, for the three months ended March 31, 2020 compared to the prior year period primarily as a result of the following activity:
Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $4.2 million.
Increases in portfolio operating expenses as follows:
Portfolio property tax expense of $1.2 million;
Maintenance and repair expense of $0.3 million;
Compensation related expenses of $0.2 million;
Portfolio insurance expense of $0.2 million;
Portfolio security expense of $0.2 million; and
Portfolio janitorial expense of $0.1 million.
Leasing commissions and legal fees increased approximately $0.4 million.
Increase in intangible amortization expense totaling $0.7 million.
Dispositions in 2019 resulted in a decrease of $0.7 million.
General and administrative expenses increased approximately $0.3 million, or 3.0%, for the three months ended March 31, 2020 compared to the prior year period primarily due to compensation expense.



25



Depreciation and amortization expense increased $4.8 million, or 11.3%, for the three months ended March 31, 2020 compared to the prior year period primarily as a result of the following activity:
Acquisitions in 2019 and 2020 and a development in 2020 resulted in an increase of $6.0 million.
Various building and tenant improvement expenditures resulted in an increase of $2.8 million.
Dispositions in 2019 resulted in a decrease of $1.4 million.
Assets that became fully depreciated resulted in a decrease of $2.6 million.

Other income (expense)
Interest expense increased $0.4 million, or 2.7%, for the three months ended March 31, 2020 compared to the prior year period. The components of interest expense are as follows:
 
THREE MONTHS ENDED MARCH 31,
CHANGE
Dollars in thousands
2020

2019

$

%

Contractual interest
$
13,398

$
13,193

$
205

1.6
%
Net discount/premium accretion
52

52


%
Deferred financing costs amortization
637

608

29

4.8
%
Interest rate swap amortization
42

42


%
Treasury hedge amortization
15


15

%
Interest cost capitalization
(421
)
(307
)
(114
)
37.1
%
Right-of-use assets financing amortization
237


237

%
Total interest expense
$
13,960

$
13,588

$
372

2.7
%
Contractual interest expense increased $0.2 million, or 1.6%, primarily due to the following activity:
The Unsecured Credit Facility rate decrease accounted for a decrease of approximately $0.4 million.
The Term Loan due 2024 accounted for an increase of approximately $0.4 million due to the following:
An increase in principal balance of $50 million accounted for an increase of approximately $0.5 million;
A decrease in the interest rate accounted for a decrease of approximately $0.5 million
The impact of the swaps accounted for an increase of approximately $0.3 million; and
Unutilized fee expense relating to the Term Loan due 2026 accounted for an increase of approximately $0.1 million.
Senior Notes due 2030 accounted for an increase of approximately $0.3 million.
Mortgage notes repayments accounted for a decrease of $0.1 million.

Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the three months ended March 31, 2020, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.



26




Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this report. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act.

Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.



27



PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors
In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, which could materially affect the Company’s business, financial condition or future results. The risks, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company’s business, financial condition, operating results or cash flows.
The ongoing COVID-19 pandemic and measures intended to prevent its spread could have a material adverse effect on the Company's business, results of operations, cash flows and financial condition.
Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.
The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across regional and global economies and financial markets. The outbreak of COVID-19 in many countries has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel.
All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects have instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants have temporarily closed their offices or clinical space or have operated on a reduced basis in response to government requirements or recommendations. Through May 5, 2020, the Company has collected 89% of April 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 7% of April 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. The tenant deferral agreements require the amounts to be repaid in the third and fourth quarters of 2020. Many of these tenants have requested, and the Company management expects more will likely seek, rent deferral or abatement for May 2020 and subsequent months, though it cannot predict how many.
The COVID-19 pandemic has also caused, and is likely to continue to cause, severe economic, market and other disruptions worldwide. There can be no assurance that conditions in the bank lending, capital and other financial markets will not continue to deteriorate as a result of the pandemic, or that the Company's access to capital and other sources of funding will not become constrained, which could adversely affect the availability and terms of future borrowings, renewals or refinancings. In addition, the deterioration of economic conditions as a result of the pandemic may ultimately decrease occupancy levels and average rent per square foot across the Company's portfolio as tenants reduce or defer their spending.
The extent of the COVID-19 pandemic’s effect on the Company's operational and financial performance will depend on future developments, including the duration, spread and intensity of the outbreak, all of which are uncertain and difficult to predict. Due to the speed with which the situation is developing, the Company is not able at this time to estimate the effect of these factors on its business, but the adverse impact on the business, results of operations, financial condition and cash flows could be material. Moreover, many risk factors set forth in our Annual Report on



28



Form 10-K for the year ended December 31, 2019 should be interpreted as heightened risks as a result of the impact of the COVID-19 pandemic.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the three months ended March 31, 2020, the Company withheld shares of Company common stock to satisfy employee tax withholding obligations payable upon the vesting of nonvested stock, as follows:
PERIOD
TOTAL NUMBER OF
SHARES PURCHASED

AVERAGE PRICE PAID
per share

TOTAL NUMBER OF SHARES
purchased as part of publicly announced plans or programs

MAXIMUM NUMBER OF SHARES
that may yet be purchased
under the plans or programs

January 1 - January 31
18,753

$
33.20



February 1 - February 29
4,810

36.46



March 1 - March 31




Total
23,563

 
 
 



29



Item 6. Exhibits
EXHIBIT
DESCRIPTION
Exhibit 4.1
Specimen Stock Certificate 2
Exhibit 4.9
Eighth Supplemental Indenture, dated March 18, 2020, by and between the Company and Branch Banking and Trust Company, as Trustee.7 
Exhibit 4.10
Form of 2.400% Senior Note due 2030 (set forth in Exhibit B to the Eighth Supplemental Indenture filed as Exhibit 4.9 hereto).
Exhibit 10.2
Amendment No. 1 to Third Amended and Restated Employment Agreement, dated February 12, 2020, between the Company and Todd J. Meredith.8
Exhibit 10.3
Amendment No. 1 to Third Amended and Restated Employment Agreement, dated February 12, 2020, between the Company and John M. Bryant, Jr..8
Exhibit 10.4
Amendment No. 1 to Amended and Restated Employment Agreement, dated February 12, 2020, between the Company and Robert E. Hull.8
Exhibit 10.5
Amendment No. 1 to Amended and Restated Employment Agreement, dated February 12, 2020, between the Company and J. Christopher Douglas.8
Exhibit 101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
Exhibit 101.SCH
XBRL Taxonomy Extension Schema Document (furnished electronically herewith)
Exhibit 101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)
Exhibit 101.LAB
XBRL Taxonomy Extension Labels Linkbase Document (furnished electronically herewith)
Exhibit 101.DEF
XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)
Exhibit 101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)
1
Filed as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed February 13, 2019 and hereby incorporated by reference.
2
Filed as an exhibit to the Company’s Registration Statement on Form S-11 (Registration No. 33-60506) filed April 2, 1993 and hereby incorporated by reference.
3
Filed as an exhibit to the Company's Current Report on Form 8-K filed May 17, 2001 and hereby incorporated by reference.
4
Filed as an exhibit to the Company's Current Report on Form 8-K filed March 26, 2013 and hereby incorporated by reference.
5
Filed as an exhibit to the Company's Current Report on Form 8-K filed April 24, 2015 and hereby incorporated by reference.



30



6
Filed as an exhibit to the Company’s Current Report on Form 8-K filed December 11, 2017 and hereby incorporated by reference.
7
Filed as an exhibit to the Company's Current Report on Form 8-K filed March 18, 2020 and hereby incorporated by reference.
8
Filed as an exhibit to the Company's Annual Report on Form 10-K filed February 12, 2020 and hereby incorporated by reference.



31



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
HEALTHCARE REALTY TRUST INCORPORATED
 
 
 
 
By:
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer
 
 
May 6, 2020



32

EX-10.1 2 hr-2020331xex101.htm EXHIBIT 10.1 Exhibit



    


Execution Version

FIRST AMENDMENT TO AMENDED AND RESTATED TERM LOAN AGREEMENT

This FIRST AMENDMENT TO AMENDED AND RESTATED TERM LOAN AGREEMENT (this “Amendment”) dated as of March 4, 2020 by and among HEALTHCARE REALTY TRUST INCORPORATED, a corporation formed under the laws of the State of Maryland (the “Borrower”), each of the Lenders party hereto and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent (the “Administrative Agent”).

WHEREAS, the Borrower, the Lenders, the Administrative Agent and certain other parties have entered into that certain Amended and Restated Term Loan Agreement dated as of May 31, 2019 (as amended and as in effect immediately prior to the effectiveness of this Amendment, the “Credit Agreement”); and

WHEREAS, the Borrower, the Lenders and the Administrative Agent desire to amend certain provisions of the Credit Agreement on the terms and conditions contained herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties hereto agree as follows:

Section 1. Amendment to Credit Agreement. Effective as of February 28, 2020, the parties hereto agree that the Credit Agreement is hereby amended by restating the definition of “Commitment Period” contained in Section 1.01 thereof in its entirety as follows:

Commitment Period” means the period from and including the Closing Date to the earlier of (a) the date which is twelve months following the Closing Date and (b) with respect to any Class, the date on which the Commitments of such Class shall have been terminated as provided herein.

Section 2. Conditions Precedent. The effectiveness of this Amendment is subject to receipt by the Administrative Agent of each of the following in form and substance satisfactory to the Administrative Agent:

(a)    a counterpart of this Amendment duly executed by the Borrower, the Administrative Agent and each of the Tranche B Term Facility Lenders;

(b)    the Administrative Agent and the Lenders shall have received a Compliance Certificate calculated on a pro forma basis for the Borrower’s fiscal quarter ending December 31, 2019;

(c)    the Administrative Agent shall have received and reviewed, with results satisfactory to the Administrative Agent and its counsel, information regarding litigation, tax, accounting, labor, insurance, pension liabilities (actual or contingent), real estate leases, material contracts, debt agreements, property ownership, environmental matters, contingent liabilities and management of the Borrower and its Subsidiaries;

(d)    a certificate of the Borrower, signed on behalf of the Borrower by the Borrower’s chief executive officer or chief financial officer, certifying that, (i) since December 31, 2019, there shall not have occurred a material adverse change in the condition (financial or otherwise), operations, business, assets, liabilities or prospects of the Consolidated Group taken as a whole or in the facts and information regarding such entities as represented to date, nor shall there have been a downgrade of the Borrower’s credit rating of two or more notches, and (ii) there is no action, suit, investigation or proceeding pending or threatened in any court or before any arbitrator or governmental authority that purports (x) to materially and adversely affect the Borrower or its subsidiaries, or (y) to affect any transaction contemplated by or under the Credit Agreement or the ability of the Borrower and its subsidiaries or any other obligor under the guarantees to perform their respective obligations under the Credit Agreement;






(e)    the Borrower and each other Credit Party shall have provided all information requested by the Administrative Agent and each Lender in order to comply with applicable “know your customer” and anti-money laundering rules and regulations, including without limitation, the Patriot Act;
    
(f)    evidence that all fees and expenses due and payable to the Administrative Agent, any of the Lenders and any of their respective Affiliates have been paid; and

(g)    such other documents, agreements and instruments as the Administrative Agent may reasonably request.

Section 3. Representations. The Borrower represents and warrants to the Administrative Agent and the Lenders that:

(a)    Corporate and Governmental Authorization; No Contravention. The execution and delivery by the Borrower of this Amendment and the performance by the Borrower of its obligations hereunder and under the Credit Agreement as amended by this Amendment are within the corporate power of the Borrower, have been duly authorized by all necessary corporate action, require no action by or in respect of, or filing with, any governmental body, agency or official or other Person (except for any such action or filing that has been taken and is in full force and effect) and do not contravene, or constitute a default under, any provision of applicable law or regulation or of the Organization Documents of the Borrower or of any material agreement, judgment, injunction, order, decree or other material instrument binding upon the Borrower or result in the creation or imposition of any Lien on any asset of the Borrower other than Liens created pursuant to the Credit Documents.

(b)    Binding Effect. This Amendment and the Credit Agreement as amended by this Amendment constitute valid and binding agreements of the Borrower, enforceable against the Borrower in accordance with their terms.

(c)    No Default. No Default or Event of Default has occurred and is continuing as of the date hereof nor will exist immediately after giving effect to this Amendment.

Section 4. Reaffirmation of Representations. The Borrower hereby repeats and reaffirms all representations and warranties made by the Borrower to the Administrative Agent and the Lenders in the Credit Agreement as amended by this Amendment and the other Credit Documents on and as of the date hereof with the same force and effect as if such representations and warranties were set forth in this Amendment in full.

Section 5. Certain References. Each reference to the Credit Agreement in any of the Credit Documents shall be deemed to be a reference to the Credit Agreement as amended by this Amendment. This Amendment is a Credit Document.

Section 6. Costs and Expenses. The Borrower shall reimburse the Administrative Agent for all reasonable out-of-pocket costs and expenses (including Attorney Costs) incurred by the Administrative Agent in connection with the preparation, negotiation and execution of this Amendment and the other agreements and documents executed and delivered in connection herewith.

Section 7. Benefits. This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

Section 8. GOVERNING LAW. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (WITHOUT TAKING INTO ACCOUNT CONFLICT OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAW OF ANOTHER JURISDICTION).

Section 9. Effect; Ratification. Except as expressly herein amended, the terms and conditions of the Credit Agreement and the other Credit Documents remain in full force and effect. The amendments contained herein shall





be deemed to have prospective application only. The Credit Agreement is hereby ratified and confirmed in all respects. Nothing in this Amendment shall limit, impair or constitute a waiver of the rights, powers or remedies available to the Administrative Agent or the Lenders under the Credit Agreement or any other Credit Document.

Section 10. Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original and shall be binding upon all parties, their successors and assigns.

Section 11. Definitions. All capitalized terms not otherwise defined herein are used herein with the respective definitions given them in the Credit Agreement.

[Signatures on Next Page]

        
    





IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to Amended and Restated Term Loan Agreement to be executed as of the date first above written.


HEALTHCARE REALTY TRUST INCORPORATED


By: /s/ J. Christopher Douglas
Name: J. Christopher Douglas
Title: Chief Financial Officer




















[Signatures Continued on Next Page]











[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]


Wells Fargo Bank, National Association, as Administrative Agent and as a Tranche B Term Facility Lender


By: /s/ Scott S. Solis
Name: Scott S. Solis
Title: Managing Director


















[Signatures Continued on Next Page]












[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

PNC BANK, National Association, as a Tranche B Term Facility Lender


By: /s/ Andrew T. White
Name: Andrew T. White
Title: Senior Vice President





















[Signatures Continued on Next Page]






[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

U.S. Bank, National Association, as a Tranche B Term Facility Lender


By: /s/ Lori Y. Jensen
Name: Lori Y. Jensen
Title: Senior Vice President





















[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

Bank of Montreal, as a Tranche B Term Facility Lender


By: /s/ Michael Kaufman
Name: Michael Kaufman
Title: Managing Director























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

Fifth Third Bank, as a Tranche B Term Facility Lender


By: /s/ Vera B. McEvoy
Name: Vera B. McEvoy
Title: Director II























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

Truist Bank, as a Tranche B Term Facility Lender


By: /s/ Richard de la Vega
Name: Richard de la Vega
Title: Vice President























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

First Tennessee Bank, National Association, as a Tranche B Term Facility Lender


By: /s/ Cathy Wind
Name: Cathy Wind
Title: SVP























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

Pinnacle Bank, as a Tranche B Term Facility Lender


By: /s/ Todd Carter
Name: Todd Carter
Title: Senior Vice President























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

Associated Bank, as a Tranche B Term Facility Lender


By: /s/ Michael J. Sedivy
Name: Michael J. Sedivy
Title: Senior Vice President























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

United Bank, as a Tranche B Term Facility Lender


By: /s/ Frederick H. Denecke
Name: Frederick H. Denecke
Title: Senior Vice President























[Signatures Continued on Next Page]





[Signature Page to First Amendment to Amended and Restated Term Loan Agreement for Healthcare Realty Trust Incorporated]

First Financial Bank, as a Tranche B Term Facility Lender


By: /s/ John E. Wilgus, II
Name: John E. Wilgus, II
Title: Senior Vice President


























EX-31.1 3 hr-2020331xex311.htm EXHIBIT 31.1 Exhibit


CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302

Exhibit 31.1
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Todd J. Meredith, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:
May 6, 2020
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer



EX-31.2 4 hr-2020331xex312.htm EXHIBIT 31.2 Exhibit


CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302
Exhibit 31.2
Healthcare Realty Trust Incorporated
Quarterly Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, J. Christopher Douglas, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Healthcare Realty Trust Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


 

Date:
May 6, 2020
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-32 5 hr-2020331xex32.htm EXHIBIT 32 Exhibit


CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350 SECTION 906
Exhibit 32
Healthcare Realty Trust Incorporated
Certification Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Healthcare Realty Trust Incorporated (the “Company”) on Form 10-Q for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Todd J. Meredith, President and Chief Executive Officer of the Company, and I, J. Christopher Douglas, Executive Vice President and Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
May 6, 2020
 
 
 
/s/ TODD J. MEREDITH
 
 
Todd J. Meredith
 
 
President and Chief Executive Officer
 
 
 
 
 
/s/ J. CHRISTOPHER DOUGLAS
 
 
J. Christopher Douglas
 
 
Executive Vice President and Chief Financial Officer



EX-101.SCH 6 hr-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Leases - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Leases - Ground Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Leases - Lease Income (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Leases - Lessor Accounting (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Notes and Bonds Payable link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Notes and Bonds Payable (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Notes and Bonds Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Real Estate Investments link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Real Estate Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hr-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hr-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hr-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Stockholders' Equity [Abstract] Dividend per share to common Stockholders (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Commitments and Contingencies Disclosure [Abstract] Other Commitments [Table] Other Commitments [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Land and Building Land and Building [Member] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Real Estate [Domain] Real Estate [Domain] Medical Office Building Expansion Medical Office Building Expansion [Member] Medical Office Building Expansion [Member] Medical Office Building Medical Office Building [Member] Medical Office Building [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] North Carolina NORTH CAROLINA Memphis, Tennessee Memphis, Tennessee [Member] Memphis, Tennessee [Member] Washington WASHINGTON Other Commitments [Line Items] Other Commitments [Line Items] Approximate Square Feet Area of Real Estate Property Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building Construction Activity, Total Funding During the Period Construction Activity, Total Funding During the Period Construction Activity, Total Funding During the Period Total amount funded Construction Activity, Total Amount Funded Construction Activity, Total Amount Funded Estimated amount to complete project Construction Activity, Estimated Remaining Fundings Construction Activity, Estimated Remaining Fundings Statement of Comprehensive Income [Abstract] Net income Net Income (Loss) Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Interest rate swaps Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract] Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Losses arising during the period on interest rate swaps Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Interest Rate Swaps, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Interest Rate Swaps, after Tax Losses on settlement of treasury rate locks arising during the period Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Settlement of Interest Rate Swaps, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Settlement of Interest Rate Swaps, after Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair Value Disclosures [Abstract] Derivative [Table] Derivative [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Derivative [Line Items] Derivative [Line Items] Notes and bonds payable Debt Instrument, Fair Value Disclosure Statement of Financial Position [Abstract] Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized shares Preferred Stock, Shares Authorized Preferred stock, issued shares Preferred Stock, Shares Issued Preferred stock, outstanding shares Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized shares Common Stock, Shares Authorized Common stock, issued shares Common Stock, Shares, Issued Common stock, outstanding shares Common Stock, Shares, Outstanding Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Los Angeles, CA CALIFORNIA Atlanta, GA GEORGIA Raleigh, NC Colorado Springs, CO Colorado City, CO [Member] Colorado City, CO [Member] Denver, CO Denver, CO [Member] Denver, CO [Member] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing [Axis] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing [Domain] Real Estate Acquisitions and Mortgage Note Financing. Real Estate Acquisition Real Estate Acquisitions [Member] Real estate acquisitions. Land Acquisition Land [Member] Real Estate and Land Acquisitions Real Estate and Land Acquisitions [Member] Real Estate and Land Acquisitions [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Purchase price Business Combination, Consideration Transferred Mortgage Notes Payable Business Combination, Consideration Transferred, Liabilities Incurred Cash consideration Payments to Acquire Businesses, Gross Real Estate Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other Square footage Business Acquisition Purchase Price Allocation Square Footage Business Acquisition Purchase Price Allocation Square Footage. Number of properties held for sale Number of Properties Held for Sale Number of properties held for sale. Derivative Instruments and Hedging Activities Disclosure [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other liabilities Other Liabilities [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap Interest Rate Swap [Member] Liability derivatives Derivative Liability, Fair Value, Gross Liability Leases [Abstract] Future Minimum Lease Payments Receivable Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block] Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Future Minimum Financing Lease Payments Finance Lease, Liability, Maturity [Table Text Block] Lease Cost Lease, Cost [Table Text Block] Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Axis] Stock Issuance Program [Domain] Stock Issuance Program [Domain] [Domain] for Stock Issuance Program [Axis] At The Market Equity Offering Program At The Market Equity Offering Program [Member] At The Market Equity Offering Program [Member] Class of Stock [Line Items] Class of Stock [Line Items] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Issuance of common stock (shares) Stock Issued During Period, Shares, New Issues Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Shares issued during period, price per share Shares Issued During Period, Price Per Share Shares Issued During Period, Price Per Share Stock repurchase program, remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Dividends declared per common share, during the period (in dollars per share) Common Stock, Dividends, Per Share, Declared Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable Fair Value, by Balance Sheet Grouping [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of properties subject to ground leases Number of Properties Subject to Ground Leases Square feet subject to ground leases Square Feet Subject to Ground Leases Square Feet Subject to Ground Leases Ground lease, initial term Lessee, Operating Lease, Term of Contract Number of prepaid ground leases Number of Ground Leases Prepaid Number of Ground Leases Prepaid Amortization of prepaid rent Amortization of Prepaid Rent Amortization of Prepaid Rent Number of non-prepaid ground leases Number of Ground Leases, Excluding Prepaid Leases Number of Ground Leases, Excluding Prepaid Leases Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Debt Disclosure [Abstract] Notes and Bonds Payable Debt Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Aggregate April tenant billings collected (percent) Aggregate Tenant Billings Collected for Period, Percent Aggregate Tenant Billings Collected for Period, Percent April tenant billings deferred under rent deferral agreements (percent) Tenant Billings Deferred under Rent Deferral Agreements, Percent Tenant Billings Deferred under Rent Deferral Agreements, Percent Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Incentive Plan Stock Incentive Plan [Member] Stock Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of the activity under the incentive plans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based awards, beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based awards, end of period Shares withheld to pay estimated withholding taxes Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Reconciliation of beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block] Reconciliation of beginning and ending common stock outstanding. Earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of the activity under the Incentive Plan Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of employee stock purchase plan activity Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Rental income Operating Lease, Lease Income Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cumulative Net Income Cumulative Net Income [Member] Cumulative Net Income [Member]. Cumulative Dividends Cumulative Dividends [Member] Cumulative Dividends [Member]. Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Common stock redemptions Stock Repurchased and Retired During Period, Value Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Net income Reclassification adjustments for losses included in net income (interest expense) Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Losses arising during the period on interest rate swaps Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax Dividends to common stockholders Dividends, Common Stock, Cash Ending balance Future Lease Payments Receivable [Abstract] Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] 2020 Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year 2021 Lessor, Operating Lease, Payments to be Received, Two Years 2022 Lessor, Operating Lease, Payments to be Received, Three Years 2023 Lessor, Operating Lease, Payments to be Received, Four Years 2024 Lessor, Operating Lease, Payments to be Received, Five Years 2025 and thereafter Lessor, Operating Lease, Payments to be Received, Thereafter Total Lessor, Operating Lease, Payments to be Received Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] OPERATING Lessee, Operating Lease, Liability, Payment, Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five 2025 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Lessee, Operating Lease, Liability, Payments, Due Discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lease liabilities Operating Lease, Liability FINANCING Finance Lease, Liability, Payment, Due [Abstract] 2020 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five 2025 and thereafter Finance Lease, Liability, Payments, Due after Year Five Total undiscounted lease payments Finance Lease, Liability, Payment, Due Discount Finance Lease, Liability, Undiscounted Excess Amount Lease liabilities Finance Lease, Liability Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Income Statement [Abstract] Revenues Revenues [Abstract] Rental income Operating Leases, Income Statement, Lease Revenue Other operating Revenue from Contract with Customer, Excluding Assessed Tax Revenues Revenues Expenses Operating Expenses [Abstract] Property operating Direct Costs of Leased and Rented Property or Equipment General and administrative General and Administrative Expense Acquisition and pursuit costs Acquisition Costs, Period Cost Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Total Expenses Operating Expenses Other Income (Expense) Nonoperating Income (Expense) [Abstract] Gain (loss) on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate Interest expense Interest Expense Interest and other income (expense), net Other Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) Net Income Basic earnings per common share (in dollars per share) Earnings Per Share, Basic Diluted earnings per common share (in dollars per share) Earnings Per Share, Diluted Weighted average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Dividends declared, per common share, during the period (in dollars per share) Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Parking Income Parking Income [Member] Parking Income [Member] Rental Lease Guaranty Rental Lease Guaranty [Member] Rental Lease Guaranty [Member] Management Fee Income Management Fee Income [Member] Management Fee Income [Member] Miscellaneous Miscellaneous [Member] Miscellaneous [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue Reconciliation of the beginning and ending common stock outstanding Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward] Reconciliation of the beginning and ending common stock outstanding. Balance, beginning of period Issuance of common stock Nonvested share-based awards, net of withheld shares Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Balance, end of period Shares withheld to pay taxes Leases Lessee, Finance Leases [Text Block] Leases Lessee, Operating Leases [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Summary of acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Employee Stock Purchase Plan Employee Stock [Member] Summary of the Employee Stock Purchase Plan activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding and exercisable, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding and exercisable, end of period (shares) Business Overview: Business Overview [Abstract] Business Overview [Abstract] Gross investment amount, total Investment in Real Estate Properties and Mortgage Notes Investment in real estate properties and mortgage notes. Number of real estate properties Number of Real Estate Investments Number of real estate investments. Number of states that the Company owns real estate in, whole units Real Estate Investments Property Owned in Number of States Real estate investments property owned in number of states. Square footage of owned real estate properties Approximate square feet for which Nationwide property management services provided by company Approximate Square Feet Provided by Company Approximate square feet for which Nationwide property management services provided by company Disaggreation of revenue Disaggregation of Revenue [Table Text Block] Real Estate Investments Acquisitions and Dispositions [Text Block] Acquisitions and dispositions. Schedule of Debt Schedule of Debt [Table Text Block] Subsequent Events Subsequent Events [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Interest Expense Interest Expense [Member] Interest Rate Swaps Interest Rate Contract [Member] Treasury Hedges Treasury Lock [Member] Settled Interest Rate Swaps LOSS RECOGNIZED IN AOCI ON DERIVATIVE Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME Operating lease cost Lease, Cost [Abstract] Operating lease expense Operating Lease, Cost Variable lease expense Variable Lease, Cost Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Interest on lease liabilities Finance Lease, Interest Expense Lease, Cost Lease, Cost Other information Leases, Operating [Abstract] Operating cash flows outflows related to operating leases Operating Lease, Payments Financing cash flows outflows related to financing leases Finance Lease, Principal Payments Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Weighted-average remaining lease term - operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term - finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate - finance leases Finance Lease, Weighted Average Discount Rate, Percent Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Mortgages Mortgages [Member] Treasury Lock Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of Credit Line of Credit [Member] Medium-term Notes Medium-term Notes [Member] Senior Notes Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] $700 million Unsecured Credit Facility Unsecured Credit Facility [Member] Unsecured Credit Facility [Member] $200 million Unsecured Term Loan Facility, net of issuance costs Term Loan due 2024 [Member] Term Loan due 2024 [Member] $150 million Unsecured Term Loan due 2026 Term Loan due 2026 [Member] Term Loan due 2026 [Member] Senior Notes due 2023, net of discount and issuance costs Senior Notes due 2023 [Member] Senior Notes due 2023 [Member] Senior Notes due 2025, net of discount and issuance costs Senior Notes due 2025 [Member] Senior Notes due 2025 [Member] Senior Notes due 2028, net of discount and issuance costs Senior Notes due 2028 [Member] Senior Notes due 2028 [Member] Senior Notes due 2030, net of discount and issuance costs Senior Notes due 2030 [Member] Senior Notes due 2030 [Member] Mortgage notes payable, net of discounts and issuance costs and including premiums Mortgage Notes Payable, Net [Member] Mortgage Notes Payable, Net [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Notional amount Derivative, Notional Amount Fixed interest rate Derivative, Fixed Interest Rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Notes and bonds payable Long-term Debt Term-loan facility Debt Instrument, Face Amount Loss on derivative instrument agreement recognized in OCI Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Outstanding principal repaid Extinguishment of Debt, Amount Area of real estate property Debt issuance costs Debt Issuance Costs, Line of Credit Arrangements, Gross Debt discount Debt Instrument, Unamortized Discount Number of Derivative Instruments Settled Number of Derivative Instruments Settled Number of Derivative Instruments Settled ASSETS Assets [Abstract] Real estate properties Real Estate Investment Property, Net [Abstract] Land Land Buildings, improvements and lease intangibles Investment Building and Building Improvements Personal property Personal Property Personal property. Construction in progress Development in Process Land held for development Land Available for Development Real estate properties, Total Real Estate Investment Property, at Cost Less accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Total real estate properties, net Real Estate Investment Property, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Assets held for sale, net Assets Held-for-sale and Discontinued Operations Net Assets held for sale and discontinued operations, net. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Financing lease right-of-use assets Finance Lease, Right-of-Use Asset Other assets, net Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Notes and bonds payable Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Liabilities of properties held for sale Disposal Group, Including Discontinued Operation, Liabilities Operating lease liabilities Financing lease liabilities Other liabilities Other Liabilities Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $.01 par value per share; 300,000 shares authorized; 134,932 and 134,706 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Cumulative net income attributable to common stockholders Cumulative Net Income Attributable to Common Stockholders Cumulative net income attributable to common stockholders. Cumulative dividends Cumulative Dividends Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Active Interest Rate Swap Active Interest Rate Swaps [Member] Active Interest Rate Swaps [Member] Number of instruments Number of Interest Rate Derivatives Held Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivatives in net liability position Derivative, Net Liability Position, Aggregate Fair Value Business Overview Nature of Operations [Policy Text Block] Nature Of Operations Policy. Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates in the Condensed Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] Revenue from Contract with Customers (Topic 606) Revenue from Contract with Customer [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Other amortization Amortization of Other Deferred Charges Share-based compensation Share-based Payment Arrangement, Noncash Expense Amortization of straight-line rent receivable (lessor) Straight-line Rent Receivable Straight-line rent receivable. Amortization of straight-line rent on operating leases (lessee) Straight-line Rent Liability Straight-line rent liability. (Gain) loss on sales of real estate assets Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation Loss from unconsolidated joint ventures Income (Loss) from Equity Method Investments Distributions from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets, including right-of-use-assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions of real estate Payments to Acquire Real Estate Development of real estate Payments to Develop Real Estate Assets Additional long-lived assets Payments to Acquire Other Productive Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Net repayments on unsecured credit facility Proceeds from (Repayments of) Lines of Credit Borrowings of notes and bonds payable Proceeds from Issuance of Other Long-term Debt Repayments on notes and bonds payable Repayments of Debt Dividends paid Payments of Ordinary Dividends, Common Stock Net proceeds from issuance of common stock Common stock redemptions Payments for Repurchase of Common Stock Settlement of treasury rate locks Payments for Hedge, Financing Activities Debt issuance and assumption costs Payments of Debt Issuance Costs Payments made on finance leases Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental Cash Flow Information Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Invoices accrued for construction, tenant improvements and other capitalized costs Capital Expenditures Incurred but Not yet Paid Mortgage notes payable assumed upon acquisition (adjusted to fair value) Notes Assumed Capitalized interest Interest Paid, Capitalized, Investing Activities Weighted average Common Shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average Common Shares outstanding Weighted Average Number of Shares Issued, Basic Nonvested shares Weighted Average Number of Shares, Restricted Stock Weighted average Common Shares—Basic Dilutive effect of employee stock purchase plan Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan Incremental common shares attributable to dilutive effect of employee stock purchase plan. Weighted average Common Shares outstanding—Diluted Net Income Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Dividends paid on nonvested share-based awards Dividend, Share-based Payment Arrangement Net income applicable to common stockholders Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic EX-101.PRE 10 hr-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) - Stock Incentive Plan - shares
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Summary of the activity under the incentive plans    
Share-based awards, beginning of period 1,754,066 1,769,863
Granted (shares) 39,344 64,771
Vested (shares) (68,649) (50,507)
Share-based awards, end of period 1,724,761 1,784,127
Restricted Stock    
Summary of the activity under the incentive plans    
Shares withheld to pay estimated withholding taxes 23,563 19,546
EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Revenue $ 2,163 $ 1,961
Parking Income    
Disaggregation of Revenue [Line Items]    
Revenue 2,051 1,734
Rental Lease Guaranty    
Disaggregation of Revenue [Line Items]    
Revenue 0 128
Management Fee Income    
Disaggregation of Revenue [Line Items]    
Revenue 78 69
Miscellaneous    
Disaggregation of Revenue [Line Items]    
Revenue $ 34 $ 30
XML 16 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
As of March 31, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
DERIVATIVE INSTRUMENT
NUMBER OF INSTRUMENTS

NOTIONAL AMOUNT
in millions
Interest rate swaps
8

$175.0

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2020.
 
BALANCE AT MARCH 31, 2020
In thousands
BALANCE SHEET LOCATION
FAIR VALUE

Derivatives designated as hedging instruments
 
 
Interest rate swaps
Other liabilities
$
14,672

Total derivatives designated as hedging instruments
 
$
14,672


Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)
The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2020 and 2019 related to the Company's outstanding interest rate swaps.
 
LOSS RECOGNIZED IN
AOCI ON DERIVATIVE
three months ended March 31,
 
(GAIN) LOSS RECLASSIFIED FROM
AOCI INTO INCOME
three months ended March 31,
In thousands
2020

2019

2020

2019

Interest rate swaps
$
9,663

$
724

Interest expense
$
271

$
(27
)
Settled treasury hedges
4,267


Interest expense
15


Settled interest rate swaps


Interest expense
42

42

 
$
13,930

$
724

Total interest expense
$
328

$
15

XML 17 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
OPERATING    
2020 $ 3,113  
2021 4,844  
2022 4,875  
2023 4,913  
2024 4,969  
2025 and thereafter 307,665  
Total undiscounted lease payments 330,379  
Discount (239,286)  
Lease liabilities 91,093 $ 91,574
FINANCING    
2020 429  
2021 754  
2022 763  
2023 774  
2024 795  
2025 and thereafter 83,404  
Total undiscounted lease payments 86,919  
Discount (68,966)  
Lease liabilities $ 17,953 $ 18,037
XML 18 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) - Designated as Hedging Instrument - Interest Rate Swap
$ in Thousands
Mar. 31, 2020
USD ($)
Derivative [Line Items]  
Liability derivatives $ 14,672
Other liabilities  
Derivative [Line Items]  
Liability derivatives $ 14,672
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues    
Rental income $ 122,644 $ 110,696
Other operating 2,163 1,961
Revenues 124,807 112,657
Expenses    
Property operating 49,552 42,725
General and administrative 8,766 8,510
Acquisition and pursuit costs 750 305
Depreciation and amortization 47,497 42,662
Total Expenses 106,565 94,202
Other Income (Expense)    
Gain (loss) on sales of real estate assets (49) 15
Interest expense (13,960) (13,588)
Interest and other income (expense), net 82 9
Total other income (expense) (13,927) (13,564)
Net Income $ 4,315 $ 4,891
Basic earnings per common share (in dollars per share) $ 0.03 $ 0.04
Diluted earnings per common share (in dollars per share) $ 0.03 $ 0.04
Weighted average common shares outstanding - basic 133,036,245 124,129,635
Weighted average common shares outstanding - diluted 133,149,566 124,231,767
Dividends declared, per common share, during the period (in dollars per share) $ 0.30 $ 0.30
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
OPERATING ACTIVITIES    
Net income $ 4,315 $ 4,891
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 47,497 42,662
Other amortization 1,491 727
Share-based compensation 2,599 2,639
Amortization of straight-line rent receivable (lessor) (1,043) (668)
Amortization of straight-line rent on operating leases (lessee) 375 390
(Gain) loss on sales of real estate assets 49 (15)
Loss from unconsolidated joint ventures 11 10
Distributions from unconsolidated joint ventures 118 88
Changes in operating assets and liabilities:    
Other assets, including right-of-use-assets (4,032) (4,971)
Accounts payable and accrued liabilities (10,005) (10,276)
Other liabilities (2,931) (673)
Net cash provided by operating activities 38,444 34,804
INVESTING ACTIVITIES    
Acquisitions of real estate (83,580) (91,787)
Development of real estate (2,451) (5,712)
Additional long-lived assets (22,164) (11,741)
Net cash used in investing activities (108,195) (109,240)
FINANCING ACTIVITIES    
Net repayments on unsecured credit facility (78,000) (2,000)
Borrowings of notes and bonds payable 298,995  
Repayments on notes and bonds payable (7,202) (1,193)
Dividends paid (40,416) (37,614)
Net proceeds from issuance of common stock 7,213 120,617
Common stock redemptions (892) (2,442)
Settlement of treasury rate locks (4,267)  
Debt issuance and assumption costs (2,646)  
Payments made on finance leases (321) 0
Net cash provided by financing activities 172,464 77,368
Increase in cash and cash equivalents 102,713 2,932
Cash and cash equivalents at beginning of period 657 8,381
Cash and cash equivalents at end of period 103,370 11,313
Supplemental Cash Flow Information    
Interest paid 11,428 11,071
Invoices accrued for construction, tenant improvements and other capitalized costs 12,830 13,509
Mortgage notes payable assumed upon acquisition (adjusted to fair value) 19,269  
Capitalized interest $ 421 $ 307
XML 21 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Common Stock    
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2020 and the year ended December 31, 2019:
 
MARCH 31, 2020

DECEMBER 31, 2019

Balance, beginning of period
134,706,154

125,279,455

Issuance of common stock
210,271

9,251,440

Nonvested share-based awards, net of withheld shares
15,781

175,259

Balance, end of period
134,932,206

134,706,154



At-The-Market Equity Offering Program
On February 14, 2020, the Company entered into sales agreements with six investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of $500.0 million of common stock. During the first quarter of 2020, the Company sold 196,250 shares under the Company's at-the-market equity offering program generating approximately $7.0 million in net proceeds at prices to the public ranging from $33.00 to $36.15 per share (weighted average of $36.09 per share). No shares were sold from March 18, 2020 through the date of this filing. The Company had $492.9 million remaining available to be sold under the current sales agreements at the date of this filing.

Common Stock Dividends
During the three months ended March 31, 2020, the Company declared and paid common stock dividends totaling $0.30 per share. On May 5, 2020, the Company declared a quarterly common stock dividend in the amount of $0.30 per share payable on May 29, 2020 to stockholders of record on May 15, 2020.
Earnings Per Common Share
The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2020 and 2019.
 
THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data
2020

2019

Weighted average common shares outstanding
 
 
Weighted average common shares outstanding
134,758,335

125,908,335

Non-vested shares
(1,722,090
)
(1,778,700
)
Weighted average common shares outstanding - basic
133,036,245

124,129,635

 
 
 
Weighted average common shares outstanding - basic
133,036,245

124,129,635

Dilutive effect of employee stock purchase plan
113,321

102,132

Weighted average common shares outstanding - diluted
133,149,566

124,231,767

 
 
 
Net Income
$
4,315

$
4,891

Dividends paid on nonvested share-based awards
(517
)
(536
)
Net income applicable to common stockholders
$
3,798

$
4,355

 
 
 
Basic earnings per common share - net income
$
0.03

$
0.04

Diluted earnings per common share - net income
$
0.03

$
0.04



Incentive Plans
A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2020 and 2019 is included in the table below.
 
THREE MONTHS ENDED MARCH 31,
 
2020

2019

Share-based awards, beginning of period
1,754,066

1,769,863

Granted
39,344

64,771

Vested
(68,649
)
(50,507
)
Share-based awards, end of period
1,724,761

1,784,127


During the three months ended March 31, 2020 and 2019, the Company withheld 23,563 and 19,546 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.
In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three months ended March 31, 2020 and 2019 is included in the table below.
 
THREE MONTHS ENDED MARCH 31,
 
2020

2019

Outstanding and exercisable, beginning of period
332,659

328,533

Granted
212,716

235,572

Exercised
(11,904
)
(14,630
)
Forfeited
(22,981
)
(16,625
)
Expired
(139,794
)
(142,074
)
Outstanding and exercisable, end of period
370,696

390,776


XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Leases
3 Months Ended
Mar. 31, 2020
Leases [Abstract]  
Leases Leases
Lessor Accounting
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2020 was $122.6 million.
Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2020 were as follows:
In thousands
 
2020
$
280,413

2021
335,188

2022
294,771

2023
250,284

2024
193,772

2025 and thereafter
514,144

 
$
1,868,572



Lessee Accounting
As of March 31, 2020, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2020, the Company had 104 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of March 31, 2020. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended March 31, 2020 and March 31, 2019, respectively.
The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of March 31, 2020 were as follows:
In thousands
OPERATING

FINANCING

2020
$
3,113

$
429

2021
4,844

754

2022
4,875

763

2023
4,913

774

2024
4,969

795

2025 and thereafter
307,665

83,404

Total undiscounted lease payments
330,379

86,919

Discount
(239,286
)
(68,966
)
Lease liabilities
$
91,093

$
17,953



The following table provides details of the Company's total lease expense for the three months ended March 31, 2020 and 2019:
 
THREE MONTHS ENDED MARCH 31,
In thousands
2020

2019

Operating lease cost
 
 
Operating lease expense
$
1,174

$
1,116

Variable lease expense
800

740

 
 
 
Finance lease cost
 
 
Amortization of right-of-use assets
70


Interest on lease liabilities
237


Total lease expense
$
2,281

$
1,856

 
 
 
Other information
 
 
Operating cash flows outflows related to operating leases
$
2,550

$
2,771

Financing cash flows outflows related to financing leases
$
321

$

Right-of-use assets obtained in exchange for new finance lease liabilities
$

$

 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
49.4

54.0

Weighted-average remaining lease term (excluding renewal options) -finance leases
64.9


Weighted-average discount rate - operating leases
5.7
%
5.5
%
Weighted-average discount rate - finance leases
5.4
%
%

Leases Leases
Lessor Accounting
The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.
The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the three months ended March 31, 2020 was $122.6 million.
Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2020 were as follows:
In thousands
 
2020
$
280,413

2021
335,188

2022
294,771

2023
250,284

2024
193,772

2025 and thereafter
514,144

 
$
1,868,572



Lessee Accounting
As of March 31, 2020, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of March 31, 2020, the Company had 104 properties totaling 8.7 million square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of 40 to 99 years with expiration dates through 2117. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had 42 prepaid ground leases as of March 31, 2020. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately $0.2 million and $0.1 million of the Company’s rental expense for the three months ended March 31, 2020 and March 31, 2019, respectively.
The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of March 31, 2020 were as follows:
In thousands
OPERATING

FINANCING

2020
$
3,113

$
429

2021
4,844

754

2022
4,875

763

2023
4,913

774

2024
4,969

795

2025 and thereafter
307,665

83,404

Total undiscounted lease payments
330,379

86,919

Discount
(239,286
)
(68,966
)
Lease liabilities
$
91,093

$
17,953



The following table provides details of the Company's total lease expense for the three months ended March 31, 2020 and 2019:
 
THREE MONTHS ENDED MARCH 31,
In thousands
2020

2019

Operating lease cost
 
 
Operating lease expense
$
1,174

$
1,116

Variable lease expense
800

740

 
 
 
Finance lease cost
 
 
Amortization of right-of-use assets
70


Interest on lease liabilities
237


Total lease expense
$
2,281

$
1,856

 
 
 
Other information
 
 
Operating cash flows outflows related to operating leases
$
2,550

$
2,771

Financing cash flows outflows related to financing leases
$
321

$

Right-of-use assets obtained in exchange for new finance lease liabilities
$

$

 
 
 
Weighted-average remaining lease term (excluding renewal options) - operating leases
49.4

54.0

Weighted-average remaining lease term (excluding renewal options) -finance leases
64.9


Weighted-average discount rate - operating leases
5.7
%
5.5
%
Weighted-average discount rate - finance leases
5.4
%
%

XML 23 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Disaggreation of revenue Below is a detail of the amounts by category:
 
THREE MONTHS ENDED
March 31,
in thousands
2020

2019

Type of Revenue
 
 
Parking income
$
2,051

$
1,734

Rental lease guaranty

128

Management fee income
78

69

Miscellaneous
34

30

 
$
2,163

$
1,961


JSON 24 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hr-2020331singlesource.htm": { "axisCustom": 2, "axisStandard": 18, "contextCount": 140, "dts": { "calculationLink": { "local": [ "hr-20200331_cal.xml" ] }, "definitionLink": { "local": [ "hr-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hr-2020331singlesource.htm" ] }, "labelLink": { "local": [ "hr-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hr-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hr-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 408, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 18, "http://healthcarerealty.com/20200331": 1, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 25 }, "keyCustom": 33, "keyStandard": 287, "memberCustom": 24, "memberStandard": 27, "nsprefix": "hr", "nsuri": "http://healthcarerealty.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://healthcarerealty.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Real Estate Investments", "role": "http://healthcarerealty.com/role/RealEstateInvestments", "shortName": "Real Estate Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:AcquisitionsAndDispositionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Leases", "role": "http://healthcarerealty.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Notes and Bonds Payable", "role": "http://healthcarerealty.com/role/NotesAndBondsPayable", "shortName": "Notes and Bonds Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Derivative Financial Instruments", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Commitments and Contingencies", "role": "http://healthcarerealty.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Stockholders' Equity", "role": "http://healthcarerealty.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Fair Value of Financial Instruments", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Subsequent Events", "role": "http://healthcarerealty.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Real Estate Investments (Tables)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsTables", "shortName": "Real Estate Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Leases (Tables)", "role": "http://healthcarerealty.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Notes and Bonds Payable (Tables)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableTables", "shortName": "Notes and Bonds Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Stockholders' Equity (Tables)", "role": "http://healthcarerealty.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "hr:InvestmentInRealEstatePropertiesAndMortgageNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_hr_ParkingIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Real Estate Investments - Acquisitions (Details)", "role": "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails", "shortName": "Real Estate Investments - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "hr:NumberOfPropertiesHeldForSale", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Leases - Lease Income (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails", "shortName": "Leases - Lease Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Leases - Lessor Accounting (Details)", "role": "http://healthcarerealty.com/role/LeasesLessorAccountingDetails", "shortName": "Leases - Lessor Accounting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Leases - Ground Leases (Details)", "role": "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "shortName": "Leases - Ground Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfPropertiesSubjectToGroundLeases", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Leases - Future Minimum Lease Payments (Details)", "role": "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "us-gaap:LeaseCostTableTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - Leases - Lease Cost (Details)", "role": "http://healthcarerealty.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "us-gaap:LeaseCostTableTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Notes and Bonds Payable (Details)", "role": "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "shortName": "Notes and Bonds Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_hr_UnsecuredCreditFacilityMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "shortName": "Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "shortName": "Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "role": "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "shortName": "Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details)", "role": "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "shortName": "Commitments and Contingencies - Construction Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_hr_MedicalOfficeBuildingExpansionMember_srt_StatementGeographicalAxis_hr_MemphisTennesseeMember", "decimals": "0", "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "shortName": "Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "hr:ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "I2020Q1Feb14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "shortName": "Stockholders' Equity (Stock Transactions - Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "I2020Q1Feb14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails", "shortName": "Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails", "shortName": "Stockholders' Equity - Summary of activity under stock-based incentive plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4_us-gaap_PlanNameAxis_hr_StockIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "role": "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "D2020Q2Apr1-May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "2", "first": true, "lang": null, "name": "hr:AggregateTenantBillingsCollectedforPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - Subsequent Events (Details)", "role": "http://healthcarerealty.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "D2020Q2Apr1-May4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "2", "first": true, "lang": null, "name": "hr:AggregateTenantBillingsCollectedforPeriodPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "hr:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationInterestRateSwapsafterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hr-2020331singlesource.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hr_AcquisitionsAndDispositionsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions and dispositions.", "label": "Acquisitions and Dispositions [Text Block]", "verboseLabel": "Real Estate Investments" } } }, "localname": "AcquisitionsAndDispositionsTextBlock", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestments" ], "xbrltype": "textBlockItemType" }, "hr_ActiveInterestRateSwapsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Active Interest Rate Swaps [Member]", "label": "Active Interest Rate Swaps [Member]", "terseLabel": "Active Interest Rate Swap" } } }, "localname": "ActiveInterestRateSwapsMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "hr_AggregateTenantBillingsCollectedforPeriodPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Tenant Billings Collected for Period, Percent", "label": "Aggregate Tenant Billings Collected for Period, Percent", "terseLabel": "Aggregate April tenant billings collected (percent)" } } }, "localname": "AggregateTenantBillingsCollectedforPeriodPercent", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "hr_AmortizationofPrepaidRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Prepaid Rent", "label": "Amortization of Prepaid Rent", "terseLabel": "Amortization of prepaid rent" } } }, "localname": "AmortizationofPrepaidRent", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ApproximateSquareFeetProvidedByCompany": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Approximate square feet for which Nationwide property management services provided by company", "label": "Approximate Square Feet Provided by Company", "verboseLabel": "Approximate square feet for which Nationwide property management services provided by company" } } }, "localname": "ApproximateSquareFeetProvidedByCompany", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "hr_AssetsHeldForSaleAndDiscontinuedOperationsNet": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets held for sale and discontinued operations, net.", "label": "Assets Held-for-sale and Discontinued Operations Net", "verboseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleAndDiscontinuedOperationsNet", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At The Market Equity Offering Program [Member]", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "At The Market Equity Offering Program" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_BusinessAcquisitionPurchasePriceAllocationSquareFootage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition Purchase Price Allocation Square Footage.", "label": "Business Acquisition Purchase Price Allocation Square Footage", "verboseLabel": "Square footage" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationSquareFootage", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "areaItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Real Property", "terseLabel": "Real Estate" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRealProperty", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Adjustments and Other", "terseLabel": "Other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValueAdjustmentsandOther", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "hr_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Overview [Abstract]", "label": "Business Overview [Abstract]", "terseLabel": "Business Overview:" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hr_ColoradoCityCOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Colorado City, CO [Member]", "label": "Colorado City, CO [Member]", "terseLabel": "Colorado Springs, CO" } } }, "localname": "ColoradoCityCOMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ConstructionActivityEstimatedRemainingFundings": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Estimated Remaining Fundings", "label": "Construction Activity, Estimated Remaining Fundings", "terseLabel": "Estimated amount to complete project" } } }, "localname": "ConstructionActivityEstimatedRemainingFundings", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Amount Funded", "label": "Construction Activity, Total Amount Funded", "terseLabel": "Total amount funded" } } }, "localname": "ConstructionActivityTotalAmountFunded", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalFundingDuringthePeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Funding During the Period", "label": "Construction Activity, Total Funding During the Period", "terseLabel": "Construction Activity, Total Funding During the Period" } } }, "localname": "ConstructionActivityTotalFundingDuringthePeriod", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_ConstructionActivityTotalFundingDuringthePeriodExcludingPurchaseofLandandBuilding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building", "label": "Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building", "terseLabel": "Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building" } } }, "localname": "ConstructionActivityTotalFundingDuringthePeriodExcludingPurchaseofLandandBuilding", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Dividends [Member].", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative Dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_CumulativeNetIncomeAttributableToCommonStockholders": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cumulative net income attributable to common stockholders.", "label": "Cumulative Net Income Attributable to Common Stockholders", "verboseLabel": "Cumulative net income attributable to common stockholders" } } }, "localname": "CumulativeNetIncomeAttributableToCommonStockholders", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_CumulativeNetIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative Net Income [Member].", "label": "Cumulative Net Income [Member]", "terseLabel": "Cumulative Net Income" } } }, "localname": "CumulativeNetIncomeMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "hr_DenverCOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denver, CO [Member]", "label": "Denver, CO [Member]", "terseLabel": "Denver, CO" } } }, "localname": "DenverCOMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "label": "Gains (Losses) on Sales of Investment Real Estate, Including Discontinued Operation", "negatedLabel": "(Gain) loss on sales of real estate assets" } } }, "localname": "GainsLossesonSalesofInvestmentRealEstateIncludingDiscontinuedOperation", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to dilutive effect of employee stock purchase plan.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan", "verboseLabel": "Dilutive effect of employee stock purchase plan" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "hr_InvestmentInRealEstatePropertiesAndMortgageNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in real estate properties and mortgage notes.", "label": "Investment in Real Estate Properties and Mortgage Notes", "terseLabel": "Gross investment amount, total" } } }, "localname": "InvestmentInRealEstatePropertiesAndMortgageNotes", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hr_ManagementFeeIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Management Fee Income [Member]", "label": "Management Fee Income [Member]", "terseLabel": "Management Fee Income" } } }, "localname": "ManagementFeeIncomeMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingExpansionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building Expansion [Member]", "label": "Medical Office Building Expansion [Member]", "terseLabel": "Medical Office Building Expansion" } } }, "localname": "MedicalOfficeBuildingExpansionMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Office Building [Member]", "label": "Medical Office Building [Member]", "terseLabel": "Medical Office Building" } } }, "localname": "MedicalOfficeBuildingMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_MemphisTennesseeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Memphis, Tennessee [Member]", "label": "Memphis, Tennessee [Member]", "terseLabel": "Memphis, Tennessee" } } }, "localname": "MemphisTennesseeMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "hr_MiscellaneousMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Miscellaneous [Member]", "label": "Miscellaneous [Member]", "terseLabel": "Miscellaneous" } } }, "localname": "MiscellaneousMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_MortgageNotesPayableNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mortgage Notes Payable, Net [Member]", "label": "Mortgage Notes Payable, Net [Member]", "terseLabel": "Mortgage notes payable, net of discounts and issuance costs and including premiums" } } }, "localname": "MortgageNotesPayableNetMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature Of Operations Policy.", "label": "Nature of Operations [Policy Text Block]", "terseLabel": "Business Overview" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Stockholders, Basic", "totalLabel": "Net income applicable to common stockholders" } } }, "localname": "NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "hr_NumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of properties held for sale.", "label": "Number of Properties Held for Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "NumberOfPropertiesHeldForSale", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "hr_NumberOfRealEstateInvestments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of real estate investments.", "label": "Number of Real Estate Investments", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateInvestments", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofDerivativeInstrumentsSettled": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Derivative Instruments Settled", "label": "Number of Derivative Instruments Settled", "terseLabel": "Number of Derivative Instruments Settled" } } }, "localname": "NumberofDerivativeInstrumentsSettled", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesExcludingPrepaidLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases, Excluding Prepaid Leases", "label": "Number of Ground Leases, Excluding Prepaid Leases", "terseLabel": "Number of non-prepaid ground leases" } } }, "localname": "NumberofGroundLeasesExcludingPrepaidLeases", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_NumberofGroundLeasesPrepaid": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of Ground Leases Prepaid", "label": "Number of Ground Leases Prepaid", "terseLabel": "Number of prepaid ground leases" } } }, "localname": "NumberofGroundLeasesPrepaid", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "hr_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationInterestRateSwapsafterTax": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Interest Rate Swaps, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Interest Rate Swaps, after Tax", "negatedTerseLabel": "Losses arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationInterestRateSwapsafterTax", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationSettlementofInterestRateSwapsafterTax": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Settlement of Interest Rate Swaps, after Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Settlement of Interest Rate Swaps, after Tax", "negatedTerseLabel": "Losses on settlement of treasury rate locks arising during the period" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationSettlementofInterestRateSwapsafterTax", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_ParkingIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Parking Income [Member]", "label": "Parking Income [Member]", "terseLabel": "Parking Income" } } }, "localname": "ParkingIncomeMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_PersonalProperty": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Personal property.", "label": "Personal Property", "terseLabel": "Personal property" } } }, "localname": "PersonalProperty", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Axis]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Axis]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingAxis", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "hr_RealEstateAcquisitionsAndMortgageNoteFinancingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate Acquisitions and Mortgage Note Financing.", "label": "Real Estate Acquisitions and Mortgage Note Financing [Domain]", "terseLabel": "Real Estate Acquisitions and Mortgage Note Financing [Domain]" } } }, "localname": "RealEstateAcquisitionsAndMortgageNoteFinancingDomain", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate acquisitions.", "label": "Real Estate Acquisitions [Member]", "terseLabel": "Real Estate Acquisition" } } }, "localname": "RealEstateAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_RealEstateInvestmentsPropertyOwnedInNumberOfStates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate investments property owned in number of states.", "label": "Real Estate Investments Property Owned in Number of States", "verboseLabel": "Number of states that the Company owns real estate in, whole units" } } }, "localname": "RealEstateInvestmentsPropertyOwnedInNumberOfStates", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "hr_RealEstateandLandAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate and Land Acquisitions [Member]", "label": "Real Estate and Land Acquisitions [Member]", "terseLabel": "Real Estate and Land Acquisitions" } } }, "localname": "RealEstateandLandAcquisitionsMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of the beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingRollForward", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "hr_ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of beginning and ending common stock outstanding.", "label": "Reconciliation of Beginning and Ending Common Stock Outstanding [Table Text Block]", "terseLabel": "Reconciliation of beginning and ending common stock outstanding" } } }, "localname": "ReconciliationOfBeginningAndEndingCommonStockOutstandingTableTextBlock", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "hr_RentalLeaseGuarantyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rental Lease Guaranty [Member]", "label": "Rental Lease Guaranty [Member]", "terseLabel": "Rental Lease Guaranty" } } }, "localname": "RentalLeaseGuarantyMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2023 [Member]", "label": "Senior Notes due 2023 [Member]", "terseLabel": "Senior Notes due 2023, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2023Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2025 [Member]", "label": "Senior Notes due 2025 [Member]", "terseLabel": "Senior Notes due 2025, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2025Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2028 [Member]", "label": "Senior Notes due 2028 [Member]", "terseLabel": "Senior Notes due 2028, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2028Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SeniorNotesdue2030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes due 2030 [Member]", "label": "Senior Notes due 2030 [Member]", "terseLabel": "Senior Notes due 2030, net of discount and issuance costs" } } }, "localname": "SeniorNotesdue2030Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_SharesIssuedDuringPeriodPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares Issued During Period, Price Per Share", "label": "Shares Issued During Period, Price Per Share", "terseLabel": "Shares issued during period, price per share" } } }, "localname": "SharesIssuedDuringPeriodPricePerShare", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hr_SquareFeetSubjecttoGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Square Feet Subject to Ground Leases", "label": "Square Feet Subject to Ground Leases", "terseLabel": "Square feet subject to ground leases" } } }, "localname": "SquareFeetSubjecttoGroundLeases", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "areaItemType" }, "hr_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive Plan [Member]", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "hr_StockIssuanceProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Axis]", "terseLabel": "Stock Issuance Program [Axis]" } } }, "localname": "StockIssuanceProgramAxis", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "hr_StockIssuanceProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Stock Issuance Program [Axis]", "label": "Stock Issuance Program [Domain]", "terseLabel": "Stock Issuance Program [Domain]" } } }, "localname": "StockIssuanceProgramDomain", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "hr_StraightLineRentReceivable": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent receivable.", "label": "Straight-line Rent Receivable", "negatedLabel": "Amortization of straight-line rent receivable (lessor)" } } }, "localname": "StraightLineRentReceivable", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_StraightlineRentLiability": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Straight-line rent liability.", "label": "Straight-line Rent Liability", "terseLabel": "Amortization of straight-line rent on operating leases (lessee)" } } }, "localname": "StraightlineRentLiability", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hr_TenantBillingsDeferredunderRentDeferralAgreementsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tenant Billings Deferred under Rent Deferral Agreements, Percent", "label": "Tenant Billings Deferred under Rent Deferral Agreements, Percent", "terseLabel": "April tenant billings deferred under rent deferral agreements (percent)" } } }, "localname": "TenantBillingsDeferredunderRentDeferralAgreementsPercent", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "hr_TermLoandue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2024 [Member]", "label": "Term Loan due 2024 [Member]", "terseLabel": "$200 million Unsecured Term Loan Facility, net of issuance costs" } } }, "localname": "TermLoandue2024Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_TermLoandue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan due 2026 [Member]", "label": "Term Loan due 2026 [Member]", "terseLabel": "$150 million Unsecured Term Loan due 2026" } } }, "localname": "TermLoandue2026Member", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "hr_UnsecuredCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unsecured Credit Facility [Member]", "label": "Unsecured Credit Facility [Member]", "terseLabel": "$700 million Unsecured Credit Facility" } } }, "localname": "UnsecuredCreditFacilityMember", "nsuri": "http://healthcarerealty.com/20200331", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r280", "r281" ], "lang": { "en-US": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r112", "r142", "r143", "r277", "r278" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r113", "r142", "r144", "r279", "r280", "r281" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CALIFORNIA", "terseLabel": "Los Angeles, CA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GEORGIA", "terseLabel": "Atlanta, GA" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_NC": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NORTH CAROLINA", "terseLabel": "North Carolina", "verboseLabel": "Raleigh, NC" } } }, "localname": "NC", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "stpr_WA": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "WASHINGTON", "terseLabel": "Washington" } } }, "localname": "WA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r250", "r269" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r30", "r33" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r31", "r33", "r36", "r172" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r243", "r244" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost", "terseLabel": "Acquisition and pursuit costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r13" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r147", "r149", "r161", "r162" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "netLabel": "Approximate Square Feet", "terseLabel": "Area of real estate property", "verboseLabel": "Square footage of owned real estate properties" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r110", "r246", "r261" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r150", "r160" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r181", "r186" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r166", "r167", "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "verboseLabel": "Purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r165", "r166", "r167", "r170" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "negatedTerseLabel": "Mortgage Notes Payable" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "verboseLabel": "Invoices accrued for construction, tenant improvements and other capitalized costs" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r17", "r74" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r67", "r74", "r79" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r67", "r211" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r122", "r252", "r265" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r121", "r123" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "verboseLabel": "Dividend per share to common Stockholders (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share, during the period (in dollars per share)", "verboseLabel": "Dividends declared, per common share, during the period (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r132" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "verboseLabel": "Common stock, outstanding shares" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value per share; 300,000 shares authorized; 134,932 and 134,706 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r39", "r41", "r42" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Notes and Bonds Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r247", "r248", "r259" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r214", "r216" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Term-loan facility" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Notes and bonds payable" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r126", "r214" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r82", "r133", "r136", "r137", "r138", "r213", "r214", "r216", "r258" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r213", "r216" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r72", "r116" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r108" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r26", "r27", "r184", "r242" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Liability derivatives" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r182", "r185", "r191", "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r178", "r182", "r191" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "auth_ref": [ "r196" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "terseLabel": "Derivatives in net liability position" } } }, "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r83", "r173", "r175", "r176", "r178", "r180", "r187", "r191", "r197", "r198", "r201" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r268" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Construction in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment": { "auth_ref": [ "r52" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense incurred and directly related to generating revenue from leased and rented property or equipment.", "label": "Direct Costs of Leased and Rented Property or Equipment", "verboseLabel": "Property operating" } } }, "localname": "DirectCostsOfLeasedAndRentedPropertyOrEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggreation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r150", "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Summary of the activity under the Incentive Plan" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends to common stockholders" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsShareBasedCompensation": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind dividends declared for award under share-based payment arrangement.", "label": "Dividend, Share-based Payment Arrangement", "negatedTerseLabel": "Dividends paid on nonvested share-based awards" } } }, "localname": "DividendsShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r86", "r90", "r91", "r92", "r93", "r96", "r256", "r272" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r48", "r86", "r90", "r91", "r92", "r93", "r96", "r256", "r272" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r46", "r66", "r72", "r270" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions from unconsolidated joint ventures" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Outstanding principal repaid" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r204", "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r204", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r221", "r226", "r235" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "FINANCING" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r220", "r234" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Financing lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Financing Lease Payments" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r234" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "2025 and thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r234" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r222", "r229" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments made on finance leases", "terseLabel": "Financing cash flows outflows related to financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r219" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Financing lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r221", "r226", "r235" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r232", "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r231", "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r49", "r50", "r72", "r254", "r273", "r274", "r275", "r276" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "terseLabel": "Gain (loss) on sales of real estate assets" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r178", "r195" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r51", "r73", "r93", "r171" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "hr_NetIncomeLossfromContinuingOperationsAvailabletoCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r46", "r72", "r109", "r115", "r253", "r270" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Loss from unconsolidated joint ventures" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets, including right-of-use-assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r44", "r107", "r212", "r215", "r257" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r58", "r75" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Capitalized interest" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r65", "r68", "r75" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r146", "r192" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Swaps" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap", "verboseLabel": "Settled Interest Rate Swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "verboseLabel": "Buildings, improvements and lease intangibles" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r5", "r18" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndBuildingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.", "label": "Land and Building [Member]", "terseLabel": "Land and Building" } } }, "localname": "LandAndBuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandAvailableForDevelopment": { "auth_ref": [ "r264" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of land available for development.", "label": "Land Available for Development", "terseLabel": "Land held for development" } } }, "localname": "LandAvailableForDevelopment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land Acquisition" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r233", "r235" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Other information" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r234" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2025 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r234" ], "calculation": { "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Ground lease, initial term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Lease Payments Receivable [Abstract]" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fifth fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Five Years", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in fourth year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Four Years", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]", "terseLabel": "Future Minimum Lease Payments Receivable" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in remainder of fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor after fifth fiscal year following latest statement of financial position date for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Thereafter", "terseLabel": "2025 and thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in third fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Three Years", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r238" ], "calculation": { "http://healthcarerealty.com/role/LeasesLessorAccountingDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payments to be received by lessor in second fiscal year following latest fiscal year for operating lease. Excludes interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.", "label": "Lessor, Operating Lease, Payments to be Received, Two Years", "terseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLessorAccountingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r16", "r249", "r263" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r2", "r3", "r120" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "verboseLabel": "Liabilities of properties held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r10", "r125", "r248", "r262" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Notes and bonds payable", "verboseLabel": "Notes and bonds payable" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r124" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MediumTermNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instruments with maturities ranging from five to ten years.", "label": "Medium-term Notes [Member]", "terseLabel": "Medium-term Notes" } } }, "localname": "MediumTermNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r67", "r69", "r73" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r37", "r40", "r47", "r73", "r95", "r255", "r271" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net Income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAssumed1": { "auth_ref": [ "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of notes assumed in noncash investing or financing activities.", "label": "Notes Assumed", "terseLabel": "Mortgage notes payable assumed upon acquisition (adjusted to fair value)" } } }, "localname": "NotesAssumed1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of instruments" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfPropertiesSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of separate real estate development properties located on land subject to ground leases.", "label": "Number of Properties Subject to Ground Leases", "terseLabel": "Number of properties subject to ground leases" } } }, "localname": "NumberOfPropertiesSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesGroundLeasesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r227", "r235" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r97", "r237", "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "OPERATING" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r220" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r223", "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows outflows related to operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r219" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r232", "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r231", "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r218" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Operating Leases, Income Statement, Lease Revenue", "terseLabel": "Rental income" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAmortizationOfDeferredCharges": { "auth_ref": [ "r53", "r72" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of other deferred costs recognized in the income statement.", "label": "Amortization of Other Deferred Charges", "terseLabel": "Other amortization" } } }, "localname": "OtherAmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r7", "r245", "r260" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Other assets, net" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]", "terseLabel": "Interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r28", "r32", "r183", "r188", "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "LOSS RECOGNIZED IN AOCI ON DERIVATIVE" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r32", "r34" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Reclassification adjustments for losses included in net income (interest expense)", "terseLabel": "(GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "auth_ref": [ "r29", "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "terseLabel": "Losses arising during the period on interest rate swaps" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax", "negatedTerseLabel": "Loss on derivative instrument agreement recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r38", "r41", "r43", "r132" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r32", "r34", "r35", "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedTerseLabel": "Reclassification adjustments for losses included in net income (interest expense)" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r251" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r181", "r199" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForHedgeFinancingActivities": { "auth_ref": [ "r64", "r70" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.", "label": "Payments for Hedge, Financing Activities", "negatedLabel": "Settlement of treasury rate locks" } } }, "localname": "PaymentsForHedgeFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Common stock redemptions" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r63" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance and assumption costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r57", "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r58" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Additional long-lived assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r58" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Acquisitions of real estate" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToDevelopRealEstateAssets": { "auth_ref": [ "r58" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to develop real estate assets is the process of adding improvements on or to a parcel of land. Such improvements may include drainage, utilities, subdividing, access, buildings, and any combination of these elements; and are generally classified as cash flow from investing activities.", "label": "Payments to Develop Real Estate Assets", "negatedLabel": "Development of real estate" } } }, "localname": "PaymentsToDevelopRealEstateAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r150", "r160" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, outstanding shares" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r59" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r60" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-term Debt", "terseLabel": "Borrowings of notes and bonds payable" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r84" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net repayments on unsecured credit facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r19", "r118" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r6", "r117" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate properties, Total" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r267" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Total real estate properties, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estate Investment Property, Net [Abstract]", "verboseLabel": "Real estate properties" } } }, "localname": "RealEstateInvestmentPropertyNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r62" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Repayments on notes and bonds payable" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r141", "r142" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Other operating" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r80", "r145" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contract with Customers (Topic 606)" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r45", "r105", "r106", "r111" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r230", "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of acquisitions" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/RealEstateInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r150", "r160" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summary of employee stock purchase plan activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r24", "r81", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Share-based awards, end of period", "periodStartLabel": "Share-based awards, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "verboseLabel": "Summary of the activity under the incentive plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r152", "r160" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding and exercisable, end of period (shares)", "periodStartLabel": "Outstanding and exercisable, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Summary of the Employee Stock Purchase Plan activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r148", "r151" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Shares withheld to pay estimated withholding taxes", "verboseLabel": "Shares withheld to pay taxes" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement", "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r12", "r132", "r139" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails", "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r12", "r132", "r139" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Nonvested share-based awards, net of withheld shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r132", "r139", "r153" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r12", "r132", "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining authorized repurchase amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r11", "r12", "r132", "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "negatedTerseLabel": "Common stock redemptions" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r14", "r15", "r114" ], "calculation": { "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails", "http://healthcarerealty.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Treasury Lock", "verboseLabel": "Treasury Hedges" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails", "http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails", "http://healthcarerealty.com/role/NotesAndBondsPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r98", "r99", "r100", "r101", "r102", "r103", "r104" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Condensed Consolidated Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r228", "r235" ], "calculation": { "http://healthcarerealty.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r89", "r93" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average Common Shares outstanding\u2014Diluted", "verboseLabel": "Weighted average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r87", "r88", "r95" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average Common Shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r87", "r93" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted average Common Shares\u2014Basic", "verboseLabel": "Weighted average common shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited", "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r88" ], "calculation": { "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "negatedTerseLabel": "Nonvested shares" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888421&loc=SL77919311-209978" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919396-209981" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919372-209981" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=82851474&loc=d3e511914-122862" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23415-158514" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23439-158514" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337411&loc=d3e23528-158515" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r282": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r284": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r285": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r286": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r287": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3581-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=SL77927221-108306" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" } }, "version": "2.1" } XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Business Overview
Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2020, the Company had gross investments of approximately $4.4 billion in 212 real estate properties located in 25 states totaling approximately 15.8 million square feet. The Company provided leasing and property management services to approximately 12.0 million square feet nationwide. Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.

Basis of Presentation
The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.
The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at March 31, 2020. A prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company.
This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.

Use of Estimates in the Condensed Consolidated Financial Statements
Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

Revenue from Contracts with Customers (Topic 606)
The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.
Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
 
THREE MONTHS ENDED
March 31,
in thousands
2020

2019

Type of Revenue
 
 
Parking income
$
2,051

$
1,734

Rental lease guaranty

128

Management fee income
78

69

Miscellaneous
34

30

 
$
2,163

$
1,961


The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.
New Accounting Pronouncements
Accounting Standards Update No. 2016-13
In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2017-04
In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2020-04
On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.
ZIP 26 0000899749-20-000049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899749-20-000049-xbrl.zip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end XML 27 R33.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases - Lease Cost (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Operating lease cost    
    Operating lease expense $ 1,174 $ 1,116
    Variable lease expense 800 740
    Amortization of right-of-use assets 70 0
    Interest on lease liabilities 237 0
    Lease, Cost 2,281 1,856
    Other information    
    Operating cash flows outflows related to operating leases 2,550 2,771
    Financing cash flows outflows related to financing leases 321 0
    Right-of-use assets obtained in exchange for new finance lease liabilities $ 0 $ 0
    Weighted-average remaining lease term - operating leases 49 years 4 months 24 days 54 years
    Weighted-average remaining lease term - finance leases 64 years 10 months 24 days  
    Weighted-average discount rate - operating leases 5.70% 5.50%
    Weighted-average discount rate - finance leases 5.40% 0.00%

    XML 28 R1.htm IDEA: XBRL DOCUMENT v3.20.1
    Cover Page - shares
    3 Months Ended
    Mar. 31, 2020
    May 01, 2020
    Cover [Abstract]    
    Document Type 10-Q  
    Document Quarterly Report true  
    Document Period End Date Mar. 31, 2020  
    Document Transition Report false  
    Entity File Number 001-11852  
    Entity Registrant Name HEALTHCARE REALTY TRUST INCORPORATED  
    Entity Incorporation, State or Country Code MD  
    Entity Tax Identification Number 62-1507028  
    Entity Address, Address Line One 3310 West End Avenue, Suite 700  
    Entity Address, City or Town Nashville  
    Entity Address, State or Province TN  
    Entity Address, Postal Zip Code 37203  
    City Area Code 615  
    Local Phone Number 269-8175  
    Title of 12(b) Security Common stock, $0.01 par value per share  
    Trading Symbol HR  
    Security Exchange Name NYSE  
    Entity Current Reporting Status Yes  
    Entity Interactive Data Current Yes  
    Entity Filer Category Large Accelerated Filer  
    Entity Small Business false  
    Entity Emerging Growth Company false  
    Entity Shell Company false  
    Entity Common Stock, Shares Outstanding   134,932,261
    Entity Central Index Key 0000899749  
    Current Fiscal Year End Date --12-31  
    Document Fiscal Year Focus 2020  
    Document Fiscal Period Focus Q1  
    Amendment Flag false  
    XML 29 R37.htm IDEA: XBRL DOCUMENT v3.20.1
    Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) - USD ($)
    $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Derivative [Line Items]    
    LOSS RECOGNIZED IN AOCI ON DERIVATIVE $ 13,930 $ 724
    (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME (328) (15)
    Interest Rate Swaps    
    Derivative [Line Items]    
    LOSS RECOGNIZED IN AOCI ON DERIVATIVE 9,663 724
    Treasury Hedges    
    Derivative [Line Items]    
    LOSS RECOGNIZED IN AOCI ON DERIVATIVE 4,267 0
    Settled Interest Rate Swaps    
    Derivative [Line Items]    
    LOSS RECOGNIZED IN AOCI ON DERIVATIVE 0 0
    Interest Expense    
    Derivative [Line Items]    
    (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME 328 15
    Interest Expense | Interest Rate Swaps    
    Derivative [Line Items]    
    (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME 271 (27)
    Interest Expense | Treasury Hedges    
    Derivative [Line Items]    
    (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME 15 0
    Interest Expense | Settled Interest Rate Swaps    
    Derivative [Line Items]    
    (GAIN) LOSS RECLASSIFIED FROM AOCI INTO INCOME $ 42 $ 42
    XML 30 R5.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
    $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Statement of Comprehensive Income [Abstract]    
    Net income $ 4,315 $ 4,891
    Interest rate swaps    
    Reclassification adjustments for losses included in net income (interest expense) 328 15
    Losses arising during the period on interest rate swaps (9,663) (724)
    Losses on settlement of treasury rate locks arising during the period (4,267) 0
    Total other comprehensive income (loss) (13,602) (709)
    Comprehensive income $ (9,287) $ 4,182
    XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.1
    Summary of Significant Accounting Policies (Policies)
    3 Months Ended
    Mar. 31, 2020
    Accounting Policies [Abstract]  
    Business Overview
    Business Overview
    Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of March 31, 2020, the Company had gross investments of approximately $4.4 billion in 212 real estate properties located in 25 states totaling approximately 15.8 million square feet. The Company provided leasing and property management services to approximately 12.0 million square feet nationwide.
    Basis of Presentation
    Basis of Presentation
    The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2019. All material intercompany transactions and balances have been eliminated in consolidation.
    The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at March 31, 2020. A prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company.
    This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2020 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties
    Use of Estimates in the Condensed Consolidated Financial Statements
    Use of Estimates in the Condensed Consolidated Financial Statements
    Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
    Revenue from Contract with Customers (Topic 606)
    Revenue from Contracts with Customers (Topic 606)
    The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance.
    Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:
     
    THREE MONTHS ENDED
    March 31,
    in thousands
    2020

    2019

    Type of Revenue
     
     
    Parking income
    $
    2,051

    $
    1,734

    Rental lease guaranty

    128

    Management fee income
    78

    69

    Miscellaneous
    34

    30

     
    $
    2,163

    $
    1,961


    The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle.
    New Accounting Pronouncements
    New Accounting Pronouncements
    Accounting Standards Update No. 2016-13
    In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

    Accounting Standards Update No. 2017-04
    In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.

    Accounting Standards Update No. 2020-04
    On March 12, 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.
    XML 32 R14.htm IDEA: XBRL DOCUMENT v3.20.1
    Commitments and Contingencies
    3 Months Ended
    Mar. 31, 2020
    Commitments and Contingencies Disclosure [Abstract]  
    Commitments and Contingencies Commitments and Contingencies
    Legal Proceedings
    The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

    Redevelopment Activity
    The Company initiated the redevelopment of a 110,883 square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. The Company funded approximately $1.5 million, excluding the purchase price of $8.7 million for the land and building. The building will continue to operate with in-place leases during construction. The Memphis Redevelopment is expected to be completed in the first quarter of 2021.

    Development Activity
    The Company completed the development of a 151,031 square foot medical office building in Seattle, Washington. As of March 31, 2020, the Company had funded approximately $54.1 million towards the development. The Company expects to fund an additional amount of approximately $10.0 million for additional tenant improvements associated with this project. The first tenant took occupancy in the first quarter of 2020.
    XML 33 R10.htm IDEA: XBRL DOCUMENT v3.20.1
    Real Estate Investments
    3 Months Ended
    Mar. 31, 2020
    Business Combinations [Abstract]  
    Real Estate Investments Real Estate Investments
    2020 Acquisitions
    The following table details the Company's acquisitions for the three months ended March 31, 2020:
    Dollars in millions
    TYPE 1
    DATE ACQUIRED
    PURCHASE PRICE

    MORTGAGE NOTES PAYABLE

    CASH
    CONSIDERATION
    2

    REAL
    ESTATE

    OTHER 3

    SQUARE FOOTAGE

    Los Angeles, CA
    MOB
    1/3/20
    $
    42.0

    $
    (19.3
    )
    $
    22.8

    $
    42.4

    $
    (0.3
    )
    86,986

    Atlanta, GA
    MOB
    2/13/20
    12.0


    11.8

    12.1

    (0.3
    )
    64,624

    Raleigh, NC
    MOB
    2/25/20
    6.3


    6.5

    6.5


    15,964

    Colorado Springs, CO
    MOB
    3/9/20
    8.2


    8.3

    8.6

    (0.3
    )
    34,210

    Denver, CO 4
    MOB
    3/13/20
    33.5


    33.2

    34.0

    (0.8
    )
    136,994

    Total real estate acquisitions
     
    $
    102.0

    $
    (19.3
    )
    $
    82.6

    $
    103.6

    $
    (1.7
    )
    338,778

    Land acquisition 5
     
     
    1.6


    1.7

    1.7



     
     
     
    $
    103.6

    $
    (19.3
    )
    $
    84.3

    $
    105.3

    $
    (1.7
    )
    338,778

    1
    MOB = medical office building.
    2
    Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
    3
    Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
    4
    Includes three properties.
    5
    The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system).

    Assets Held for Sale
    As of March 31, 2020 and December 31, 2019, the Company had no properties classified as held for sale.
    XML 36 R43.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - shares
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Summary of the Employee Stock Purchase Plan activity    
    Outstanding and exercisable, beginning of period (shares) 332,659 328,533
    Granted (shares) 212,716 235,572
    Exercised (shares) (11,904) (14,630)
    Forfeited (shares) (22,981) (16,625)
    Expired (shares) (139,794) (142,074)
    Outstanding and exercisable, end of period (shares) 370,696 390,776
    XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.1
    Summary of Significant Accounting Policies (Details)
    ft² in Millions, $ in Billions
    Mar. 31, 2020
    USD ($)
    ft²
    state
    property
    Business Overview:  
    Gross investment amount, total | $ $ 4.4
    Number of real estate properties | property 212
    Number of states that the Company owns real estate in, whole units | state 25
    Square footage of owned real estate properties 15.8
    Approximate square feet for which Nationwide property management services provided by company 12.0
    XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.1
    Notes and Bonds Payable (Tables)
    3 Months Ended
    Mar. 31, 2020
    Debt Disclosure [Abstract]  
    Schedule of Debt
    The table below details the Company’s notes and bonds payable. 
     
    MATURITY DATES
    BALANCE AS OF
    EFFECTIVE INTEREST RATE
    as of 3/31/2020

    Dollars in thousands
    3/31/2020

    12/31/2019

    $700 million Unsecured Credit Facility
    5/23
    $
    215,000

    $
    293,000

    1.89
    %
    $200 million Unsecured Term Loan Facility, net of issuance costs 1
    5/24
    199,069

    199,013

    3.20
    %
    $150 million Unsecured Term Loan due 2026 2
    6/26


    N/A

    Senior Notes due 2023, net of discount and issuance costs
    4/23
    248,647

    248,540

    3.95
    %
    Senior Notes due 2025, net of discount and issuance costs 3
    5/25
    248,584

    248,522

    4.08
    %
    Senior Notes due 2028, net of discount and issuance costs
    1/28
    295,768

    295,651

    3.84
    %
    Senior Notes due 2030, net of discount and issuance costs 4
    3/30
    296,211


    2.71
    %
    Mortgage notes payable, net of discounts and issuance costs and including premiums
    7/20-5/40
    141,175

    129,343

    4.70
    %
     
     
    $
    1,644,454

    $
    1,414,069

     

    1
    The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
    2
    As of March 31, 2020, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until May 29, 2020 to draw against the commitments.
    3
    The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.
    4
    The effective interest rate includes the impact of the $4.3 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.
    XML 39 hr-2020331singlesource_htm.xml IDEA: XBRL DOCUMENT 0000899749 2020-01-01 2020-03-31 0000899749 2020-05-01 0000899749 2019-12-31 0000899749 2020-03-31 0000899749 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeDividendsMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeNetIncomeMember 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000899749 hr:CumulativeDividendsMember 2020-03-31 0000899749 hr:CumulativeDividendsMember 2019-01-01 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000899749 hr:CumulativeDividendsMember 2019-12-31 0000899749 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeNetIncomeMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeDividendsMember 2020-01-01 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000899749 2018-12-31 0000899749 us-gaap:CommonStockMember 2020-03-31 0000899749 2019-03-31 0000899749 us-gaap:CommonStockMember 2018-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000899749 hr:CumulativeDividendsMember 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:CommonStockMember 2019-12-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2020-03-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000899749 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000899749 hr:CumulativeNetIncomeMember 2018-12-31 0000899749 hr:CumulativeNetIncomeMember 2019-12-31 0000899749 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899749 us-gaap:CommonStockMember 2019-03-31 0000899749 hr:MiscellaneousMember 2020-01-01 2020-03-31 0000899749 hr:MiscellaneousMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2020-01-01 2020-03-31 0000899749 hr:ParkingIncomeMember 2020-01-01 2020-03-31 0000899749 hr:RentalLeaseGuarantyMember 2019-01-01 2019-03-31 0000899749 hr:RentalLeaseGuarantyMember 2020-01-01 2020-03-31 0000899749 hr:ParkingIncomeMember 2019-01-01 2019-03-31 0000899749 hr:ManagementFeeIncomeMember 2019-01-01 2019-03-31 0000899749 us-gaap:LandMember 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:CA hr:RealEstateAcquisitionsMember 2020-01-03 2020-01-03 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-02-13 0000899749 hr:RealEstateAcquisitionsMember 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoCityCOMember hr:RealEstateAcquisitionsMember 2020-03-09 0000899749 hr:MedicalOfficeBuildingMember hr:ColoradoCityCOMember hr:RealEstateAcquisitionsMember 2020-03-09 2020-03-09 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:GA hr:RealEstateAcquisitionsMember 2020-02-13 2020-02-13 0000899749 us-gaap:LandMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:NC hr:RealEstateAcquisitionsMember 2020-02-25 0000899749 hr:MedicalOfficeBuildingMember stpr:CA hr:RealEstateAcquisitionsMember 2020-01-03 0000899749 hr:RealEstateAcquisitionsMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:NC hr:RealEstateAcquisitionsMember 2020-02-25 2020-02-25 0000899749 hr:RealEstateandLandAcquisitionsMember 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:DenverCOMember hr:RealEstateAcquisitionsMember 2020-03-09 2020-03-09 0000899749 hr:MedicalOfficeBuildingMember hr:DenverCOMember hr:RealEstateAcquisitionsMember 2020-03-09 0000899749 srt:MaximumMember 2020-03-31 0000899749 srt:MinimumMember 2020-03-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2019-12-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:TermLoandue2024Member us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2019-12-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2023Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:SeniorNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:MortgageNotesPayableNetMember us-gaap:MortgagesMember 2020-03-31 0000899749 hr:SeniorNotesdue2028Member us-gaap:SeniorNotesMember 2019-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0000899749 hr:UnsecuredCreditFacilityMember us-gaap:LineOfCreditMember 2020-03-31 0000899749 hr:TermLoandue2026Member us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2030Member us-gaap:SeniorNotesMember 2020-03-04 0000899749 us-gaap:MortgagesMember 2020-02-03 0000899749 us-gaap:MortgagesMember 2020-02-03 2020-02-03 0000899749 hr:SeniorNotesdue2025Member us-gaap:InterestRateSwapMember us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-01-01 2020-03-31 0000899749 hr:TermLoandue2024Member us-gaap:InterestRateSwapMember us-gaap:MediumTermNotesMember 2020-01-01 2020-03-31 0000899749 hr:SeniorNotesdue2025Member us-gaap:TreasuryLockMember us-gaap:SeniorNotesMember 2020-03-04 2020-03-04 0000899749 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-02-25 0000899749 hr:ActiveInterestRateSwapsMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-02-24 0000899749 us-gaap:TreasuryLockMember 2020-03-04 2020-03-04 0000899749 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateContractMember 2020-01-01 2020-03-31 0000899749 us-gaap:TreasuryLockMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:TreasuryLockMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000899749 us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember stpr:WA 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:MemphisTennesseeMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingMember hr:MemphisTennesseeMember us-gaap:LandAndBuildingMember 2020-01-01 2020-03-31 0000899749 hr:MedicalOfficeBuildingExpansionMember hr:MemphisTennesseeMember 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2019-03-31 0000899749 us-gaap:EmployeeStockMember 2020-03-31 0000899749 us-gaap:EmployeeStockMember 2018-12-31 0000899749 us-gaap:EmployeeStockMember 2019-12-31 0000899749 hr:StockIncentivePlanMember 2020-01-01 2020-03-31 0000899749 hr:StockIncentivePlanMember 2018-12-31 0000899749 hr:StockIncentivePlanMember 2019-12-31 0000899749 hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 hr:StockIncentivePlanMember 2020-03-31 0000899749 hr:StockIncentivePlanMember 2019-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2019-01-01 2019-03-31 0000899749 srt:MinimumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 us-gaap:RestrictedStockMember hr:StockIncentivePlanMember 2020-01-01 2020-03-31 0000899749 us-gaap:SubsequentEventMember 2020-05-06 0000899749 srt:MaximumMember hr:AtTheMarketEquityOfferingProgramMember 2020-01-01 2020-03-31 0000899749 us-gaap:SubsequentEventMember hr:AtTheMarketEquityOfferingProgramMember 2020-03-18 2020-05-06 0000899749 2020-02-14 0000899749 us-gaap:SubsequentEventMember 2020-05-29 2020-05-29 0000899749 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000899749 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000899749 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000899749 us-gaap:SubsequentEventMember 2020-04-01 2020-05-04 0000899749 us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 hr:Lease iso4217:USD shares hr:derivative shares hr:swap_agreement hr:treasury_lock iso4217:USD utreg:sqft hr:state hr:property pure false --12-31 Q1 2020 2020-03-31 0000899749 0 0.30 0.30 0.01 0.01 300000000 300000000 134706000 134932000 134706000 134932000 0.01 0.01 50000000 50000000 0 0 0 0 10-Q true false 001-11852 HEALTHCARE REALTY TRUST INCORPORATED MD 62-1507028 3310 West End Avenue, Suite 700 Nashville TN 37203 615 269-8175 Common stock, $0.01 par value per share HR NYSE Yes Yes Large Accelerated Filer false false false 134932261 319882000 289751000 4126046000 3986326000 10783000 10538000 0 48731000 24647000 24647000 4481358000 4359993000 1164462000 1121102000 3316896000 3238891000 103370000 657000 20000 37000 125040000 126177000 12615000 12667000 189708000 185426000 3747649000 3563855000 1644454000 1414069000 64574000 78517000 74000 145000 91093000 91574000 17953000 18037000 70073000 61504000 1888221000 1663846000 0 0 1349000 1347000 3494123000 3485003000 19777000 6175000 1131619000 1127304000 2747886000 2707470000 1859428000 1900009000 3747649000 3563855000 122644000 110696000 2163000 1961000 124807000 112657000 49552000 42725000 8766000 8510000 750000 305000 47497000 42662000 106565000 94202000 -49000 15000 13960000 13588000 82000 9000 -13927000 -13564000 4315000 4891000 0.03 0.04 0.03 0.04 133036000 124130000 133150000 124232000 0.30 0.30 4315000 4891000 -328000 -15000 9663000 724000 4267000 0 -13602000 -709000 -9287000 4182000 1347000 3485003000 -6175000 1127304000 -2707470000 1900009000 2000 7319000 7321000 798000 798000 2599000 2599000 4315000 4315000 -328000 -328000 -13930000 -13930000 40416000 40416000 1349000 3494123000 -19777000 1131619000 -2747886000 1859428000 1253000 3180284000 -902000 1088119000 -2552112000 1716642000 38000 120462000 120500000 570000 570000 1000 2638000 2639000 4891000 4891000 -15000 -15000 -724000 -724000 37614000 37614000 1292000 3302814000 -1611000 1093010000 -2589726000 1805779000 4315000 4891000 47497000 42662000 1491000 727000 2599000 2639000 1043000 668000 375000 390000 -49000 15000 -11000 -10000 118000 88000 4032000 4971000 -10005000 -10276000 -2931000 -673000 38444000 34804000 83580000 91787000 2451000 5712000 22164000 11741000 -108195000 -109240000 -78000000 -2000000 298995000 7202000 1193000 40416000 37614000 7213000 120617000 892000 2442000 4267000 2646000 321000 172464000 77368000 102713000 2932000 657000 8381000 103370000 11313000 11428000 11071000 12830000 13509000 19269000 421000 307000 <div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Overview</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had gross investments of approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$4.4 billion</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> in </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>212</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> real estate properties located in </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>25</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> states totaling approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>15.8 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>12.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square feet nationwide. </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Square footage and property count disclosures in these Notes to the Company's Condensed Consolidated Financial Statements are unaudited.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at March 31, 2020. A prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties, such as the impact of the COVID-19 pandemic.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.794087665647304%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #ffffff;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">in thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Type of Revenue</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Rental lease guaranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Management fee income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Miscellaneous</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle. </span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">New Accounting Pronouncements</span></div><div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2016-13</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2020-04</span></div><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On March 12, 2020, the FASB issued ASU 2020-04, </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;font-style:italic;">Reference Rate Reform (Topic 848)</span>. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. <div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Overview</span></div><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that owns, leases, manages, acquires, finances, develops and redevelops income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had gross investments of approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$4.4 billion</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> in </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>212</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> real estate properties located in </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>25</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> states totaling approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>15.8 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square feet. The Company provided leasing and property management services to approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>12.0 million</span></span> square feet nationwide. 4400000000 212 25 15800000 12000000.0 <div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. All material intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company considered the impact of COVID-19 on these assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position at March 31, 2020. A prolonged outbreak could have a material adverse impact on the financial results and business operations of the Company. </span></div><span style="font-family:Century,serif;font-size:9pt;color:#000000;">This interim financial information should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2020</span> for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties <div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates in the Condensed Consolidated Financial Statements</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.</span></div> <div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue from Contracts with Customers (Topic 606)</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company recognizes certain revenue under the core principle of Topic 606. This requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Lease revenue is not within the scope of Topic 606. To achieve the core principle, the Company applies the five step model specified in the guidance. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Revenue that is accounted for under Topic 606 is segregated on the Company’s Condensed Consolidated Statements of Income in the Other operating line item. This line item includes parking income, rental lease guaranty income, management fee income and other miscellaneous income. Below is a detail of the amounts by category:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.794087665647304%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #ffffff;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">in thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Type of Revenue</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Rental lease guaranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Management fee income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Miscellaneous</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div>The Company’s major types of revenue that are accounted for under Topic 606 that are listed above are all accounted for as the performance obligation is satisfied. The performance obligations that are identified for each of these items are satisfied over time, and the Company recognizes revenue monthly based on this principle. Below is a detail of the amounts by category:<div style="line-height:140%;padding-bottom:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.794087665647304%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #ffffff;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">in thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Type of Revenue</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Parking income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,734</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Rental lease guaranty</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>128</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Management fee income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Miscellaneous</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,163</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 2051000 1734000 0 128000 78000 69000 34000 30000 2163000 1961000 <div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">New Accounting Pronouncements</span></div><div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2016-13</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost and certain other financial instruments be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. Operating lease receivables, representing the majority of the Company's receivables, are not within the scope of the new standard. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2017-04</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." This update eliminates Step 2 of the goodwill impairment test. As such, an entity will perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value. This standard is effective for the Company for annual and interim periods beginning after December 15, 2019. The Company adopted this standard as of January 1, 2020. There was not a material impact to the Condensed Consolidated Financial Statements resulting from the adoption of this standard.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Accounting Standards Update No. 2020-04</span></div><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On March 12, 2020, the FASB issued ASU 2020-04, </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;font-style:italic;">Reference Rate Reform (Topic 848)</span>. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. Real Estate Investments<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2020 Acquisitions</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table details the Company's acquisitions for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:18%;"/><td style="width:6%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in millions</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">TYPE </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DATE ACQUIRED</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">PURCHASE PRICE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MORTGAGE NOTES PAYABLE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CASH<br/>CONSIDERATION </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">REAL </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">ESTATE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OTHER </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">3</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">SQUARE FOOTAGE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Los Angeles, CA</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1/3/20</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,986</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Atlanta, GA</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2/13/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Raleigh, NC</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2/25/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Colorado Springs, CO</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/9/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Denver, CO </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">4</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/13/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.8</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>136,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Total real estate acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>102.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>103.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>338,778</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Land acquisition </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">5</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>103.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>338,778</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Includes three properties.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system). </span></div></td></tr></table><div style="line-height:140%;padding-bottom:4px;padding-top:0px;text-align:left;padding-left:24px;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Assets Held for Sale</span></div><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>no</span></span> properties classified as held for sale. <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table details the Company's acquisitions for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:18%;"/><td style="width:6%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in millions</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">TYPE </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DATE ACQUIRED</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">PURCHASE PRICE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MORTGAGE NOTES PAYABLE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CASH<br/>CONSIDERATION </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">REAL </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">ESTATE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OTHER </span><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">3</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">SQUARE FOOTAGE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Los Angeles, CA</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1/3/20</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>22.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,986</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Atlanta, GA</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2/13/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64,624</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Raleigh, NC</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2/25/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Colorado Springs, CO</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/9/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34,210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Denver, CO </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">4</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">MOB</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/13/20</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>34.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(0.8</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>136,994</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Total real estate acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>102.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>103.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>338,778</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Land acquisition </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">5</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>103.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(19.3</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>84.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>105.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>338,778</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">MOB = medical office building.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Includes three properties.</span></div></td></tr></table><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5</span></div><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system). </span></div> 42000000.0 19300000 22800000 42400000 -300000 86986 12000000.0 0 11800000 12100000 -300000 64624 6300000 0 6500000 6500000 0 15964 8200000 0 8300000 8600000 -300000 34210 33500000 0 33200000 34000000.0 -800000 136994 102000000.0 19300000 82600000 103600000 -1700000 338778 1600000 0 1700000 1700000 0 0 103600000 19300000 84300000 105300000 -1700000 338778 0 Leases<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lessor Accounting</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> was </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$122.6 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:26.911314984709477%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:37%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>280,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>335,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>294,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>250,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>193,772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>514,144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,868,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lessee Accounting </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>104</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> properties totaling </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>8.7 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>40</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> to </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>99</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> years with expiration dates through </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2117</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>42</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> prepaid ground leases as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.2 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.1 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of the Company’s rental expense for the three months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and March 31, 2019, respectively.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s future lease payments (primarily for its </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>62</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> non-prepaid ground leases) as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.11416921508665%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OPERATING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FINANCING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>429</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>307,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>83,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>330,379</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,919</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Discount</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(239,286</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,966</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>91,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>17,953</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.0835881753313%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Operating lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Variable lease expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,281</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Other information</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>49.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>54.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> Leases<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lessor Accounting</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s properties generally are leased pursuant to non-cancelable, fixed-term operating leases with expiration dates through 2035. Some leases provide for fixed rent renewal terms in addition to market rent renewal terms. Some leases provide the lessee, during the term of the lease, with an option or right of first refusal to purchase the leased property. The Company’s portfolio of single-tenant net leases generally requires the lessee to pay minimum rent and all taxes (including property tax), insurance, maintenance and other operating costs associated with the leased property.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company's leases typically have escalators that are either based on a stated percentage or an index such as CPI (consumer price index). In addition, most of the Company's leases include nonlease components, such as reimbursement of operating expenses as additional rent, or include the reimbursement of expected operating expenses as part of the lease payment. The Company adopted an accounting policy to combine lease and nonlease components. Rent escalators based on indices and reimbursements of operating expenses that are not included in the lease rate are considered variable lease payments. Variable payments are recognized in the period earned. Lease income for the Company's operating leases recognized for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> was </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$122.6 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:26.911314984709477%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:37%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>280,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>335,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>294,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>250,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>193,772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>514,144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,868,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Lessee Accounting </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company was obligated, as the lessee, under operating lease agreements consisting primarily of the Company’s ground leases. As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>104</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> properties totaling </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>8.7 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square feet that were held under ground leases. Some of the ground leases' renewal terms are based on fixed rent renewal terms and others have market rent renewal terms. These ground leases typically have initial terms of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>40</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> to </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>99</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> years with expiration dates through </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2117</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. Any rental increases related to the Company’s ground leases are generally either stated or based on the CPI. The Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>42</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> prepaid ground leases as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. The amortization of the prepaid rent, included in the operating lease right-of-use asset, represented approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.2 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.1 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of the Company’s rental expense for the three months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and March 31, 2019, respectively.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s future lease payments (primarily for its </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>62</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> non-prepaid ground leases) as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.11416921508665%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OPERATING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FINANCING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>429</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>307,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>83,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>330,379</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,919</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Discount</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(239,286</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,966</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>91,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>17,953</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.0835881753313%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Operating lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Variable lease expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,281</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Other information</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>49.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>54.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 122600000 <div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:26.911314984709477%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:37%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>280,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>335,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>294,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>250,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>193,772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>514,144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,868,572</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 280413000 335188000 294771000 250284000 193772000 514144000 1868572000 104 8700000 P40Y P99Y 42 200000 100000 <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s future lease payments (primarily for its </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>62</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> non-prepaid ground leases) as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.11416921508665%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OPERATING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FINANCING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>429</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>307,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>83,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>330,379</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,919</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Discount</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(239,286</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,966</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>91,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>17,953</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s future lease payments (primarily for its </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>62</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> non-prepaid ground leases) as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> were as follows:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.11416921508665%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">OPERATING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FINANCING</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2020</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>429</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2021</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,844</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2023</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2024</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>795</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>307,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>83,404</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total undiscounted lease payments</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>330,379</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>86,919</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Discount</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(239,286</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,966</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>91,093</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>17,953</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 62 3113000 429000 4844000 754000 4875000 763000 4913000 774000 4969000 795000 307665000 83404000 330379000 86919000 239286000 68966000 91093000 17953000 <div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table provides details of the Company's total lease expense for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.0835881753313%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Operating lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Variable lease expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Finance lease cost</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Amortization of right-of-use assets</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total lease expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,281</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,856</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Other information</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Operating cash flows outflows related to operating leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,550</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Financing cash flows outflows related to financing leases</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>49.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>54.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average remaining lease term (excluding renewal options) -finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - operating leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.7</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.5</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted-average discount rate - finance leases</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>5.4</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 1174000 1116000 800000 740000 70000 0 237000 0 2281000 1856000 2550000 2771000 321000 0 0 0 P49Y4M24D P54Y P64Y10M24D 0.057 0.055 0.054 0 Notes and Bonds Payable<div style="line-height:140%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below details the Company’s notes and bonds payable. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:41%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MATURITY DATES</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE AS OF</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">EFFECTIVE INTEREST RATE </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">as of 3/31/2020</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">3/31/2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">12/31/2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$700 million Unsecured Credit Facility</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/23</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>215,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>293,000</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.89</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$200 million Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/24</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>199,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>199,013</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.20</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$150 million Unsecured Term Loan due 2026 </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">6/26</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4/23</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,540</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.95</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">3</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/25</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,522</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4.08</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1/28</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>295,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>295,651</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.84</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2030, net of discount and issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">4</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/30</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>296,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2.71</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">7/20-5/40</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>141,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>129,343</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4.70</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,644,454</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,414,069</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of interest rate swaps on $</span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>175.0 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> at a weighted average rate of </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2.29%</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> (plus the applicable margin rate, currently </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>100</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">As of March 31, 2020, there were </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>no</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> outstanding loans under the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$150.0 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until May 29, 2020 to draw against the commitments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$1.7 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;text-transform:default;"><span>$4.3 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Changes in Debt Structure</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">February 3, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company repaid in full a mortgage note payable bearing interest at a rate of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>6.10%</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> per annum with an outstanding principal of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$5.9 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. The mortgage note encumbered a </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>68,860</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square foot property in Oklahoma.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 4, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company issued </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$300.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>2.40%</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, payable semi-annually on </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 15</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">September 15</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$1.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and the Company incurred approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$2.8 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> in debt issuance costs. Concurrent with this transaction, the Company settled </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>two</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> treasury rate locks for </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$4.3 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>2.71%</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.</span></div> <div style="line-height:140%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below details the Company’s notes and bonds payable. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:41%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MATURITY DATES</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE AS OF</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">EFFECTIVE INTEREST RATE </span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">as of 3/31/2020</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">3/31/2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">12/31/2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$700 million Unsecured Credit Facility</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/23</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>215,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>293,000</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1.89</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$200 million Unsecured Term Loan Facility, net of issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/24</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>199,069</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>199,013</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.20</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">$150 million Unsecured Term Loan due 2026 </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">6/26</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">N/A</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2023, net of discount and issuance costs</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4/23</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,647</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,540</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.95</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2025, net of discount and issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">3</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">5/25</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>248,522</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4.08</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2028, net of discount and issuance costs</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1/28</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>295,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>295,651</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3.84</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Senior Notes due 2030, net of discount and issuance costs </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">4</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3/30</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>296,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2.71</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Mortgage notes payable, net of discounts and issuance costs and including premiums</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">7/20-5/40</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>141,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>129,343</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4.70</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,644,454</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,414,069</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of interest rate swaps on $</span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>175.0 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> at a weighted average rate of </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>2.29%</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> (plus the applicable margin rate, currently </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>100</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> basis points).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">2</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">As of March 31, 2020, there were </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>no</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> outstanding loans under the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$150.0 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until May 29, 2020 to draw against the commitments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">3</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$1.7 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets. </span></div></td></tr></table><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">4</span></div><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">The effective interest rate includes the impact of the </span><span style="font-family:Gotham Book;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;text-transform:default;"><span>$4.3 million</span></span><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"> settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.</span></div> 215000000 293000000 0.0189 199069000 199013000 0.0320 0 0 248647000 248540000 0.0395 248584000 248522000 0.0408 295768000 295651000 0.0384 296211000 0 0.0271 141175000 129343000 0.0470 1644454000 1414069000 175000000.0 0.0229 1 0 150000000.0 -1700000 -4300000 0.0610 5900000 68860 300000000.0 0.0240 1000000.0 2800000 2 -4300000 0.0271 Derivative Financial Instruments<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Risk Management Objective of Using Derivatives</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flow Hedges of Interest Rate Risk</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">February 24 and 25, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company entered into </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>two</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> treasury rate locks totaling </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$75.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$40.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, respectively. The treasury rate locks were settled for an aggregate amount of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$4.3 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> on </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 4, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10-year term of the notes.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>eight</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.318042813455655%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:41%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:35%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DERIVATIVE INSTRUMENT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">NUMBER OF INSTRUMENTS</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">NOTIONAL AMOUNT</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">in millions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$175.0</span></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:73.39449541284404%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:58%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE AT MARCH 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE SHEET LOCATION</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Other liabilities</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>14,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>14,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below presents the effect of cash flow hedge accounting on AOCI during the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> related to the Company's outstanding interest rate swaps.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">LOSS RECOGNIZED IN </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">AOCI ON DERIVATIVE</span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">three months ended March 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">(GAIN) LOSS RECLASSIFIED FROM </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">AOCI INTO INCOME</span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>9,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(27</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Settled treasury hedges</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>13,930</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total interest expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company estimates that </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$4.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> will be reclassified from AOCI to interest expense over the next 12 months.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Credit-risk-related Contingent Features</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of March 31, 2020, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$15.2 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">. As of March 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement.</span></div> 2 75000000.0 40000000.0 -4300000 <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>eight</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:48.318042813455655%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:41%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:35%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DERIVATIVE INSTRUMENT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">NUMBER OF INSTRUMENTS</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">NOTIONAL AMOUNT</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">in millions</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$175.0</span></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 8 8 175000000.0 <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:73.39449541284404%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:58%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE AT MARCH 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">BALANCE SHEET LOCATION</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Other liabilities</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>14,672</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Total derivatives designated as hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>14,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 14672000 14672000 <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below presents the effect of cash flow hedge accounting on AOCI during the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> related to the Company's outstanding interest rate swaps.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">LOSS RECOGNIZED IN </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">AOCI ON DERIVATIVE</span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">three months ended March 31,</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">(GAIN) LOSS RECLASSIFIED FROM </span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">AOCI INTO INCOME</span></div><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">three months ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In thousands</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest rate swaps</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>9,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(27</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Settled treasury hedges</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Settled interest rate swaps</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Interest expense</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>13,930</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>724</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Total interest expense</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 9663000 724000 271000 -27000 4267000 0 15000 0 0 0 42000 42000 13930000 724000 328000 15000 4000000.0 15200000 Commitments and Contingencies<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Legal Proceedings</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Redevelopment Activity</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company initiated the redevelopment of a </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>110,883</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square foot medical office building in Memphis, Tennessee ("Memphis Redevelopment") in December 2019. The Company funded approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$1.5 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, excluding the purchase price of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$8.7 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> for the land and building. The building will continue to operate with in-place leases during construction. The Memphis Redevelopment is expected to be completed in the first quarter of 2021.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Development Activity</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company completed the development of a </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>151,031</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> square foot medical office building in Seattle, Washington. As of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company had funded approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$54.1 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> towards the development. The Company expects to fund an additional amount of approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> for additional tenant improvements associated with this project. The first tenant took occupancy in the first quarter of 2020.</span></div> 110883 1500000 8700000 151031 54100000 10000000.0 Stockholders' Equity<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock    </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.84097859327217%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:58%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MARCH 31, 2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DECEMBER 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Balance, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,706,154</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Issuance of common stock</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>210,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>9,251,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Nonvested share-based awards, net of withheld shares </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>175,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Balance, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,932,206</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,706,154</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">At-The-Market Equity Offering Program</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">On </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">February 14, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company entered into sales agreements with </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">six</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> investment banks to allow sales under its at-the-market equity offering program of up to an aggregate of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of common stock. During the first quarter of 2020, the Company sold </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>196,250</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> shares under the Company's at-the-market equity offering program generating approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$7.0 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> in net proceeds at prices to the public ranging from </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$33.00</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> to </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$36.15</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> per share (weighted average of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$36.09</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> per share). </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>No</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> shares were sold from </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 18, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> through the date of this filing. The Company had </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$492.9 million</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> remaining available to be sold under the current sales agreements at the date of this filing.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock Dividends</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">During the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company declared and paid common stock dividends totaling </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.30</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> per share. On </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">May 5, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company declared a quarterly common stock dividend in the amount of </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>$0.30</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> per share payable on </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">May 29, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> to stockholders of record on</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">May 15, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Earnings Per Common Share</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The Company uses the two-class method of computing net earnings per common shares. The Company's nonvested share-based awards are considered participating securities pursuant to the two-class method. The following table sets forth the computation of basic and diluted earnings per common share for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in thousands, except per share data</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;">Weighted average common shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,758,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>125,908,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Non-vested shares</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1,722,090</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1,778,700</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,036,245</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,036,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>113,321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>102,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Weighted average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,149,566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,231,767</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(517</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(536</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,798</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,355</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Basic earnings per common share - net income </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Diluted earnings per common share - net income </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;padding-bottom:4px;text-align:justify;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div><div style="line-height:130%;padding-bottom:4px;text-align:justify;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Incentive Plans</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> is included in the table below.</span></div><div style="line-height:140%;padding-bottom:4px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:66%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,754,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Granted</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Vested </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,649</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(50,507</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Share-based awards, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,724,761</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,784,127</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;"><br/></span></div><div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">During the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company withheld </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>23,563</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>19,546</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested. </span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">In addition to the share-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> is included in the table below.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:66%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>332,659</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Granted</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>212,716</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Exercised</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(11,904</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(14,630</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Forfeited</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(22,981</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(16,625</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Expired</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(139,794</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(142,074</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>370,696</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>390,776</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and the year ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">:</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.84097859327217%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:58%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">MARCH 31, 2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">DECEMBER 31, 2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Balance, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,706,154</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>125,279,455</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Issuance of common stock</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>210,271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>9,251,440</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Nonvested share-based awards, net of withheld shares </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>15,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>175,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Balance, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,932,206</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,706,154</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:130%;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;"><br/></span></div> 134706154 125279455 210271 9251440 15781 175259 134932206 134706154 500000000.0 196250 7000000.0 33.00 36.15 36.09 0 492900000 0.30 0.30 The following table sets forth the computation of basic and diluted earnings per common share for the <span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in thousands, except per share data</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;">Weighted average common shares outstanding</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>134,758,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>125,908,335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Non-vested shares</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1,722,090</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(1,778,700</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,036,245</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Weighted average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,036,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,129,635</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Dilutive effect of employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>113,321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>102,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Weighted average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>133,149,566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>124,231,767</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;">Net Income</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,891</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Dividends paid on nonvested share-based awards</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(517</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(536</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Net income applicable to common stockholders</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>3,798</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>4,355</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Basic earnings per common share - net income </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Diluted earnings per common share - net income </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>0.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 134758335 125908335 1722090 1778700 133036245 124129635 133036245 124129635 113321 102132 133149566 124231767 4315000 4891000 517000 536000 3798000 4355000 0.03 0.04 0.03 0.04 <div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">A summary of the activity under the Company's share-based incentive plans for the </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> is included in the table below.</span></div><div style="line-height:140%;padding-bottom:4px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:66%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Share-based awards, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,754,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,769,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Granted</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39,344</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>64,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Vested </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(68,649</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(50,507</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Share-based awards, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,724,761</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,784,127</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;"><br/></span></div> 1754066 1769863 39344 64771 68649 50507 1724761 1784127 23563 19546 A summary of the activity under the Purchase Plan for the <span style="font-family:Century,serif;font-size:9pt;color:#000000;">three</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> months ended </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> is included in the table below.</span><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:74.82161060142711%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:66%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:middle;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">THREE MONTHS ENDED MARCH 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Outstanding and exercisable, beginning of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>332,659</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>328,533</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Granted</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>212,716</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>235,572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Exercised</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(11,904</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(14,630</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Forfeited</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(22,981</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(16,625</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Expired</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(139,794</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>(142,074</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Outstanding and exercisable, end of period</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>370,696</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:normal;text-decoration:none;"><span>390,776</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div> 332659 328533 212716 235572 11904 14630 22981 16625 139794 142074 370696 390776 Fair Value of Financial Instruments<div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:9pt;padding-left:0px;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Cash and cash equivalents</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> - The carrying amount approximates fair value due to the short term maturity of these investments. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:9pt;padding-left:0px;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:9pt;padding-left:0px;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Senior Notes and Mortgage Notes payable</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:140%;font-size:9pt;padding-left:0px;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:140%;text-align:left;font-size:9pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.5pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">Interest rate swap agreements</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.</span></div></td></tr></table><div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.35575942915392%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">MARCH 31, 2020</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #ffffff;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">DECEMBER 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in millions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CARRYING VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CARRYING VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Notes and bonds payable </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,644.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,706.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,414.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,425.8</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</span></div> <div style="line-height:140%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">The table below details the fair values and carrying values for notes and bonds payable at </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">March 31, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> and </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">December 31, 2019</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.35575942915392%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;font-weight:bold;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">MARCH 31, 2020</span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #ffffff;"><div style="text-align:center;font-size:5.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:5.75pt;color:#ffffff;font-style:normal;font-weight:bold;text-decoration:none;">DECEMBER 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dollars in millions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CARRYING VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">CARRYING VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:6pt;color:#2c2c2c;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;">Notes and bonds payable </span><span style="font-family:Gotham Book,sans-serif;font-size:7.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,644.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,706.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,414.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Univers Next Pro Light,sans-serif;font-size:7.5pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>1,425.8</span></span></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Century,serif;font-size:9pt;"><br/></span></div><div style="line-height:140%;font-size:6.25pt;padding-left:0px;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">1</span></div><div style="line-height:140%;text-align:left;font-size:6.25pt;"><span style="font-family:Gotham Book,sans-serif;font-size:6.25pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.</span></div> 1644500000 1706700000 1414100000 1425800000 Subsequent Events<div style="line-height:130%;padding-top:4px;text-align:left;font-size:7.75pt;"><span style="font-family:Gotham Medium,sans-serif;font-size:7.75pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">COVID-19 Update</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.</span></div><div style="line-height:140%;padding-bottom:8px;text-align:left;font-size:9pt;"><span style="font-family:Century,serif;font-size:9pt;color:#000000;">All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects have instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants have temporarily closed their offices or clinical space or have operated on a reduced basis in response to government requirements or recommendations. Through </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">May 5, 2020</span><span style="font-family:Century,serif;font-size:9pt;color:#000000;">, the Company has collected </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>89%</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of April 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately </span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"><span>7%</span></span><span style="font-family:Century,serif;font-size:9pt;color:#000000;"> of April 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. However, if tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants, including the Coronavirus Aid, Relief, and Economic Security Act or the “CARES Act".</span></div> 0.89 0.07 XML 40 R16.htm IDEA: XBRL DOCUMENT v3.20.1
    Fair Value of Financial Instruments
    3 Months Ended
    Mar. 31, 2020
    Fair Value Disclosures [Abstract]  
    Fair Value of Financial Instruments Fair Value of Financial Instruments
    The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.
    Cash and cash equivalents - The carrying amount approximates fair value due to the short term maturity of these investments.
    Borrowings under the Unsecured Credit Facility and the Term Loan Due 2024 - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.
    Senior Notes and Mortgage Notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company’s current interest rates for similar types of borrowing arrangements.
    Interest rate swap agreements - Interest rate swap agreements are recorded in other liabilities on the Company's Consolidated Balance Sheets at fair value. Fair value is estimated by utilizing pricing models that consider forward yield curves and discount rates.
    The table below details the fair values and carrying values for notes and bonds payable at March 31, 2020 and December 31, 2019.
     
    MARCH 31, 2020
    DECEMBER 31, 2019
    Dollars in millions
    CARRYING VALUE

    FAIR VALUE

    CARRYING VALUE

    FAIR VALUE

    Notes and bonds payable 1
    $
    1,644.5

    $
    1,706.7

    $
    1,414.1

    $
    1,425.8


    1
    Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
    XML 41 R12.htm IDEA: XBRL DOCUMENT v3.20.1
    Notes and Bonds Payable
    3 Months Ended
    Mar. 31, 2020
    Debt Disclosure [Abstract]  
    Notes and Bonds Payable Notes and Bonds Payable
    The table below details the Company’s notes and bonds payable. 
     
    MATURITY DATES
    BALANCE AS OF
    EFFECTIVE INTEREST RATE
    as of 3/31/2020

    Dollars in thousands
    3/31/2020

    12/31/2019

    $700 million Unsecured Credit Facility
    5/23
    $
    215,000

    $
    293,000

    1.89
    %
    $200 million Unsecured Term Loan Facility, net of issuance costs 1
    5/24
    199,069

    199,013

    3.20
    %
    $150 million Unsecured Term Loan due 2026 2
    6/26


    N/A

    Senior Notes due 2023, net of discount and issuance costs
    4/23
    248,647

    248,540

    3.95
    %
    Senior Notes due 2025, net of discount and issuance costs 3
    5/25
    248,584

    248,522

    4.08
    %
    Senior Notes due 2028, net of discount and issuance costs
    1/28
    295,768

    295,651

    3.84
    %
    Senior Notes due 2030, net of discount and issuance costs 4
    3/30
    296,211


    2.71
    %
    Mortgage notes payable, net of discounts and issuance costs and including premiums
    7/20-5/40
    141,175

    129,343

    4.70
    %
     
     
    $
    1,644,454

    $
    1,414,069

     

    1
    The effective interest rate includes the impact of interest rate swaps on $175.0 million at a weighted average rate of 2.29% (plus the applicable margin rate, currently 100 basis points).
    2
    As of March 31, 2020, there were no outstanding loans under the $150.0 million unsecured term loan due June 2026. This term loan has a delayed draw feature that allows the Company until May 29, 2020 to draw against the commitments.
    3
    The effective interest rate includes the impact of the $1.7 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.
    4
    The effective interest rate includes the impact of the $4.3 million settlement of a forward-starting interest rate swap that is included in Accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets.

    Changes in Debt Structure
    On February 3, 2020, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.10% per annum with an outstanding principal of $5.9 million. The mortgage note encumbered a 68,860 square foot property in Oklahoma.
    On March 4, 2020, the Company issued $300.0 million of unsecured senior notes due 2030 (the "Senior Notes due 2030") in a registered public offering. The Senior Notes due 2030 bear interest at 2.40%, payable semi-annually on March 15 and September 15, beginning September 15, 2020, and are due on March 15, 2030, unless redeemed earlier by the Company. The notes were issued at a discount of approximately $1.0 million and the Company incurred approximately $2.8 million in debt issuance costs. Concurrent with this transaction, the Company settled two treasury rate locks for $4.3 million. Inclusive of the discount, debt issuance costs and settlement of the treasury rate locks, the effective interest rate was 2.71%. The Senior Notes due 2030 have various financial covenants that are required to be met on a quarterly and annual basis.
    XML 42 R39.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) - shares
    3 Months Ended 12 Months Ended
    Mar. 31, 2020
    Dec. 31, 2019
    Reconciliation of the beginning and ending common stock outstanding    
    Balance, beginning of period 134,706,000  
    Balance, end of period 134,932,000 134,706,000
    Common Stock    
    Reconciliation of the beginning and ending common stock outstanding    
    Balance, beginning of period 134,706,154 125,279,455
    Issuance of common stock 210,271 9,251,440
    Nonvested share-based awards, net of withheld shares 15,781 175,259
    Balance, end of period 134,932,206 134,706,154
    XML 43 R3.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
    Mar. 31, 2020
    Dec. 31, 2019
    Statement of Financial Position [Abstract]    
    Preferred stock, par value (dollars per share) $ 0.01 $ 0.01
    Preferred stock, authorized shares 50,000,000 50,000,000
    Preferred stock, issued shares 0 0
    Preferred stock, outstanding shares 0 0
    Common stock, par value (dollars per share) $ 0.01 $ 0.01
    Common stock, authorized shares 300,000,000 300,000,000
    Common stock, issued shares 134,932,000 134,706,000
    Common stock, outstanding shares 134,932,000 134,706,000
    XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases - Ground Leases (Details)
    ft² in Millions, $ in Millions
    3 Months Ended
    Mar. 31, 2020
    USD ($)
    ft²
    Lease
    property
    Mar. 31, 2019
    USD ($)
    Lessee, Lease, Description [Line Items]    
    Number of properties subject to ground leases | property 104  
    Square feet subject to ground leases | ft² 8.7  
    Number of prepaid ground leases 42  
    Amortization of prepaid rent | $ $ 0.2 $ 0.1
    Number of non-prepaid ground leases 62  
    Minimum    
    Lessee, Lease, Description [Line Items]    
    Ground lease, initial term 40 years  
    Maximum    
    Lessee, Lease, Description [Line Items]    
    Ground lease, initial term 99 years  
    XML 45 R7.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Statement of Stockholders' Equity [Abstract]    
    Dividend per share to common Stockholders (in dollars per share) $ 0.30 $ 0.30
    XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.1
    Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details)
    $ in Millions
    Mar. 04, 2020
    USD ($)
    Mar. 31, 2020
    USD ($)
    swap_agreement
    Feb. 25, 2020
    USD ($)
    treasury_lock
    Feb. 24, 2020
    USD ($)
    Derivative [Line Items]        
    Derivatives in net liability position   $ 15.2    
    Treasury Lock        
    Derivative [Line Items]        
    Number of instruments | treasury_lock     2  
    Notional amount     $ 40.0 $ 75.0
    Loss on derivative instrument agreement recognized in OCI $ 4.3      
    Active Interest Rate Swap        
    Derivative [Line Items]        
    Interest rate cash flow hedge gain (loss) to be reclassified to interest expense during the next 12 months   $ 4.0    
    Cash Flow Hedging | Designated as Hedging Instrument | Interest Rate Swap        
    Derivative [Line Items]        
    Number of instruments | swap_agreement   8    
    Notional amount   $ 175.0    
    XML 47 R41.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    3 Months Ended
    Mar. 31, 2020
    Mar. 31, 2019
    Weighted average Common Shares outstanding    
    Weighted average Common Shares outstanding 134,758,335 125,908,335
    Nonvested shares (1,722,090) (1,778,700)
    Weighted average Common Shares—Basic 133,036,245 124,129,635
    Dilutive effect of employee stock purchase plan 113,321 102,132
    Weighted average Common Shares outstanding—Diluted 133,149,566 124,231,767
    Net Income $ 4,315 $ 4,891
    Dividends paid on nonvested share-based awards (517) (536)
    Net income applicable to common stockholders $ 3,798 $ 4,355
    Basic earnings per common share (in dollars per share) $ 0.03 $ 0.04
    Diluted earnings per common share (in dollars per share) $ 0.03 $ 0.04
    XML 48 R45.htm IDEA: XBRL DOCUMENT v3.20.1
    Subsequent Events (Details) - Subsequent Event
    1 Months Ended
    May 04, 2020
    Apr. 30, 2020
    Subsequent Event [Line Items]    
    Aggregate April tenant billings collected (percent) 89.00%  
    April tenant billings deferred under rent deferral agreements (percent)   7.00%
    XML 49 R24.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity (Tables)
    3 Months Ended
    Mar. 31, 2020
    Equity [Abstract]  
    Reconciliation of beginning and ending common stock outstanding
    The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2020 and the year ended December 31, 2019:
     
    MARCH 31, 2020

    DECEMBER 31, 2019

    Balance, beginning of period
    134,706,154

    125,279,455

    Issuance of common stock
    210,271

    9,251,440

    Nonvested share-based awards, net of withheld shares
    15,781

    175,259

    Balance, end of period
    134,932,206

    134,706,154



    Earnings (loss) per share The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2020 and 2019.
     
    THREE MONTHS ENDED MARCH 31,
    Dollars in thousands, except per share data
    2020

    2019

    Weighted average common shares outstanding
     
     
    Weighted average common shares outstanding
    134,758,335

    125,908,335

    Non-vested shares
    (1,722,090
    )
    (1,778,700
    )
    Weighted average common shares outstanding - basic
    133,036,245

    124,129,635

     
     
     
    Weighted average common shares outstanding - basic
    133,036,245

    124,129,635

    Dilutive effect of employee stock purchase plan
    113,321

    102,132

    Weighted average common shares outstanding - diluted
    133,149,566

    124,231,767

     
     
     
    Net Income
    $
    4,315

    $
    4,891

    Dividends paid on nonvested share-based awards
    (517
    )
    (536
    )
    Net income applicable to common stockholders
    $
    3,798

    $
    4,355

     
     
     
    Basic earnings per common share - net income
    $
    0.03

    $
    0.04

    Diluted earnings per common share - net income
    $
    0.03

    $
    0.04


    Summary of the activity under the Incentive Plan
    A summary of the activity under the Company's share-based incentive plans for the three months ended March 31, 2020 and 2019 is included in the table below.
     
    THREE MONTHS ENDED MARCH 31,
     
    2020

    2019

    Share-based awards, beginning of period
    1,754,066

    1,769,863

    Granted
    39,344

    64,771

    Vested
    (68,649
    )
    (50,507
    )
    Share-based awards, end of period
    1,724,761

    1,784,127


    Summary of employee stock purchase plan activity A summary of the activity under the Purchase Plan for the three months ended March 31, 2020 and 2019 is included in the table below.
     
    THREE MONTHS ENDED MARCH 31,
     
    2020

    2019

    Outstanding and exercisable, beginning of period
    332,659

    328,533

    Granted
    212,716

    235,572

    Exercised
    (11,904
    )
    (14,630
    )
    Forfeited
    (22,981
    )
    (16,625
    )
    Expired
    (139,794
    )
    (142,074
    )
    Outstanding and exercisable, end of period
    370,696

    390,776


    XML 50 R20.htm IDEA: XBRL DOCUMENT v3.20.1
    Real Estate Investments (Tables)
    3 Months Ended
    Mar. 31, 2020
    Business Combinations [Abstract]  
    Summary of acquisitions
    The following table details the Company's acquisitions for the three months ended March 31, 2020:
    Dollars in millions
    TYPE 1
    DATE ACQUIRED
    PURCHASE PRICE

    MORTGAGE NOTES PAYABLE

    CASH
    CONSIDERATION
    2

    REAL
    ESTATE

    OTHER 3

    SQUARE FOOTAGE

    Los Angeles, CA
    MOB
    1/3/20
    $
    42.0

    $
    (19.3
    )
    $
    22.8

    $
    42.4

    $
    (0.3
    )
    86,986

    Atlanta, GA
    MOB
    2/13/20
    12.0


    11.8

    12.1

    (0.3
    )
    64,624

    Raleigh, NC
    MOB
    2/25/20
    6.3


    6.5

    6.5


    15,964

    Colorado Springs, CO
    MOB
    3/9/20
    8.2


    8.3

    8.6

    (0.3
    )
    34,210

    Denver, CO 4
    MOB
    3/13/20
    33.5


    33.2

    34.0

    (0.8
    )
    136,994

    Total real estate acquisitions
     
    $
    102.0

    $
    (19.3
    )
    $
    82.6

    $
    103.6

    $
    (1.7
    )
    338,778

    Land acquisition 5
     
     
    1.6


    1.7

    1.7



     
     
     
    $
    103.6

    $
    (19.3
    )
    $
    84.3

    $
    105.3

    $
    (1.7
    )
    338,778

    1
    MOB = medical office building.
    2
    Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.
    3
    Includes other assets acquired, liabilities assumed, and intangibles recognized at acquisition.
    4
    Includes three properties.
    5
    The Company acquired land parcels under four existing buildings (previously ground leased from the hospital system).
    XML 51 R28.htm IDEA: XBRL DOCUMENT v3.20.1
    Real Estate Investments - Acquisitions (Details)
    $ in Millions
    3 Months Ended
    Mar. 09, 2020
    USD ($)
    ft²
    Feb. 25, 2020
    USD ($)
    ft²
    Feb. 13, 2020
    USD ($)
    ft²
    Jan. 03, 2020
    USD ($)
    ft²
    Mar. 31, 2020
    USD ($)
    ft²
    Dec. 31, 2019
    property
    Business Acquisition [Line Items]            
    Number of properties held for sale | property           0
    Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price         $ 102.0  
    Mortgage Notes Payable         (19.3)  
    Cash consideration         82.6  
    Real Estate         103.6  
    Other         $ (1.7)  
    Square footage | ft²         338,778  
    Land Acquisition            
    Business Acquisition [Line Items]            
    Purchase price         $ 1.6  
    Mortgage Notes Payable         0.0  
    Cash consideration         1.7  
    Real Estate         1.7  
    Other         $ 0.0  
    Square footage | ft²         0  
    Real Estate and Land Acquisitions            
    Business Acquisition [Line Items]            
    Purchase price         $ 103.6  
    Mortgage Notes Payable         (19.3)  
    Cash consideration         84.3  
    Real Estate         105.3  
    Other         $ (1.7)  
    Square footage | ft²         338,778  
    Medical Office Building | Los Angeles, CA | Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price       $ 42.0    
    Mortgage Notes Payable       (19.3)    
    Cash consideration       22.8    
    Real Estate       42.4    
    Other       $ (0.3)    
    Square footage | ft²       86,986    
    Medical Office Building | Atlanta, GA | Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price     $ 12.0      
    Mortgage Notes Payable     0.0      
    Cash consideration     11.8      
    Real Estate     12.1      
    Other     $ (0.3)      
    Square footage | ft²     64,624      
    Medical Office Building | Raleigh, NC | Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price   $ 6.3        
    Mortgage Notes Payable   0.0        
    Cash consideration   6.5        
    Real Estate   6.5        
    Other   $ 0.0        
    Square footage | ft²   15,964        
    Medical Office Building | Colorado Springs, CO | Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price $ 8.2          
    Mortgage Notes Payable 0.0          
    Cash consideration 8.3          
    Real Estate 8.6          
    Other $ (0.3)          
    Square footage | ft² 34,210          
    Medical Office Building | Denver, CO | Real Estate Acquisition            
    Business Acquisition [Line Items]            
    Purchase price $ 33.5          
    Mortgage Notes Payable 0.0          
    Cash consideration 33.2          
    Real Estate 34.0          
    Other $ (0.8)          
    Square footage | ft² 136,994          
    XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 140 320 1 false 52 0 false 11 false false R1.htm 0001000 - Document - Cover Page Sheet http://healthcarerealty.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Statement Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedStatement Condensed Consolidated Statements of Equity (Unaudited) Statement Statements 6 false false R7.htm 1004001 - Statement - Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfEquityUnauditedParenthetical Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthcarerealty.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Real Estate Investments Sheet http://healthcarerealty.com/role/RealEstateInvestments Real Estate Investments Notes 10 false false R11.htm 2103100 - Disclosure - Leases Sheet http://healthcarerealty.com/role/Leases Leases Notes 11 false false R12.htm 2104100 - Disclosure - Notes and Bonds Payable Notes http://healthcarerealty.com/role/NotesAndBondsPayable Notes and Bonds Payable Notes 12 false false R13.htm 2105100 - Disclosure - Derivative Financial Instruments Sheet http://healthcarerealty.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 2106100 - Disclosure - Commitments and Contingencies Sheet http://healthcarerealty.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2108100 - Disclosure - Stockholders' Equity Sheet http://healthcarerealty.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2109100 - Disclosure - Fair Value of Financial Instruments Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 16 false false R17.htm 2110100 - Disclosure - Subsequent Events Sheet http://healthcarerealty.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://healthcarerealty.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 2302301 - Disclosure - Real Estate Investments (Tables) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsTables Real Estate Investments (Tables) Tables http://healthcarerealty.com/role/RealEstateInvestments 20 false false R21.htm 2303301 - Disclosure - Leases (Tables) Sheet http://healthcarerealty.com/role/LeasesTables Leases (Tables) Tables http://healthcarerealty.com/role/Leases 21 false false R22.htm 2304301 - Disclosure - Notes and Bonds Payable (Tables) Notes http://healthcarerealty.com/role/NotesAndBondsPayableTables Notes and Bonds Payable (Tables) Tables http://healthcarerealty.com/role/NotesAndBondsPayable 22 false false R23.htm 2305301 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://healthcarerealty.com/role/DerivativeFinancialInstruments 23 false false R24.htm 2308301 - Disclosure - Stockholders' Equity (Tables) Sheet http://healthcarerealty.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://healthcarerealty.com/role/StockholdersEquity 24 false false R25.htm 2309301 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://healthcarerealty.com/role/FairValueOfFinancialInstruments 25 false false R26.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 2401404 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://healthcarerealty.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 27 false false R28.htm 2402402 - Disclosure - Real Estate Investments - Acquisitions (Details) Sheet http://healthcarerealty.com/role/RealEstateInvestmentsAcquisitionsDetails Real Estate Investments - Acquisitions (Details) Details 28 false false R29.htm 2403402 - Disclosure - Leases - Lease Income (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseIncomeDetails Leases - Lease Income (Details) Details 29 false false R30.htm 2403403 - Disclosure - Leases - Lessor Accounting (Details) Sheet http://healthcarerealty.com/role/LeasesLessorAccountingDetails Leases - Lessor Accounting (Details) Details 30 false false R31.htm 2403404 - Disclosure - Leases - Ground Leases (Details) Sheet http://healthcarerealty.com/role/LeasesGroundLeasesDetails Leases - Ground Leases (Details) Details 31 false false R32.htm 2403405 - Disclosure - Leases - Future Minimum Lease Payments (Details) Sheet http://healthcarerealty.com/role/LeasesFutureMinimumLeasePaymentsDetails Leases - Future Minimum Lease Payments (Details) Details 32 false false R33.htm 2403406 - Disclosure - Leases - Lease Cost (Details) Sheet http://healthcarerealty.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 33 false false R34.htm 2404402 - Disclosure - Notes and Bonds Payable (Details) Notes http://healthcarerealty.com/role/NotesAndBondsPayableDetails Notes and Bonds Payable (Details) Details http://healthcarerealty.com/role/NotesAndBondsPayableTables 34 false false R35.htm 2405402 - Disclosure - Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsDesignatedAsCashFlowHedgesDetails Derivative Financial Instruments - Derivative Instruments Designated as Cash Flow Hedges (Details) Details 35 false false R36.htm 2405403 - Disclosure - Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsFairValueOfDerivativeInstrumentsOnBalanceSheetDetails Derivative Financial Instruments - Fair Value of Derivative Instruments on the Balance Sheet (Details) Details 36 false false R37.htm 2405404 - Disclosure - Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Sheet http://healthcarerealty.com/role/DerivativeFinancialInstrumentsEffectOfCashFlowHedgingOnAociDetails Derivative Financial Instruments - Effect of Cash Flow Hedging on AOCI (Details) Details 37 false false R38.htm 2406401 - Disclosure - Commitments and Contingencies - Construction Activity (Details) Sheet http://healthcarerealty.com/role/CommitmentsAndContingenciesConstructionActivityDetails Commitments and Contingencies - Construction Activity (Details) Details 38 false false R39.htm 2408402 - Disclosure - Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityReconciliationOfBeginningAndEndingCommonStockOutstandingDetails Stockholders' Equity - Reconciliation of beginning and ending common stock outstanding (Details) Details 39 false false R40.htm 2408403 - Disclosure - Stockholders' Equity (Stock Transactions - Narrative) (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityStockTransactionsNarrativeDetails Stockholders' Equity (Stock Transactions - Narrative) (Details) Details http://healthcarerealty.com/role/StockholdersEquityTables 40 false false R41.htm 2408406 - Disclosure - Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Sheet http://healthcarerealty.com/role/StockholdersEquityComputationOfBasicAndDilutedEarningsLossPerCommonShareDetails Stockholders' Equity - Computation of basic and diluted earnings (loss) per common share (Details) Details 41 false false R42.htm 2408407 - Disclosure - Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderStockBasedIncentivePlansDetails Stockholders' Equity - Summary of activity under stock-based incentive plans (Details) Details 42 false false R43.htm 2408408 - Disclosure - Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Sheet http://healthcarerealty.com/role/StockholdersEquitySummaryOfActivityUnderEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of activity under Employee Stock Purchase Plan (Details) Details 43 false false R44.htm 2409402 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://healthcarerealty.com/role/FairValueOfFinancialInstrumentsTables 44 false false R45.htm 2410401 - Disclosure - Subsequent Events (Details) Sheet http://healthcarerealty.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://healthcarerealty.com/role/SubsequentEvents 45 false false All Reports Book All Reports hr-2020331singlesource.htm hr-20200331.xsd hr-20200331_cal.xml hr-20200331_def.xml hr-20200331_lab.xml hr-20200331_pre.xml hr-2020331xex101.htm hr-2020331xex311.htm hr-2020331xex312.htm hr-2020331xex32.htm http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.1
    Stockholders' Equity (Stock Transactions - Narrative) (Details) - USD ($)
    2 Months Ended 3 Months Ended
    May 29, 2020
    May 06, 2020
    Mar. 31, 2020
    Mar. 31, 2019
    Feb. 14, 2020
    Class of Stock [Line Items]          
    Stock repurchase program, authorized amount         $ 500,000,000.0
    Proceeds from issuance of common stock     $ 7,213,000 $ 120,617,000  
    Dividends declared per common share, during the period (in dollars per share)     $ 0.30 $ 0.30  
    At The Market Equity Offering Program          
    Class of Stock [Line Items]          
    Issuance of common stock (shares)     196,250    
    Proceeds from issuance of common stock     $ 7,000,000.0    
    Shares issued during period, price per share     $ 36.09    
    Subsequent Event          
    Class of Stock [Line Items]          
    Stock repurchase program, remaining authorized repurchase amount   $ 492,900,000      
    Dividends declared per common share, during the period (in dollars per share) $ 0.30        
    Subsequent Event | At The Market Equity Offering Program          
    Class of Stock [Line Items]          
    Issuance of common stock (shares)   0      
    Minimum | At The Market Equity Offering Program          
    Class of Stock [Line Items]          
    Shares issued during period, price per share     33.00    
    Maximum | At The Market Equity Offering Program          
    Class of Stock [Line Items]          
    Shares issued during period, price per share     $ 36.15    
    XML 54 R44.htm IDEA: XBRL DOCUMENT v3.20.1
    Fair Value of Financial Instruments (Details) - USD ($)
    $ in Millions
    Mar. 31, 2020
    Dec. 31, 2019
    Carrying Value    
    Derivative [Line Items]    
    Notes and bonds payable $ 1,644.5 $ 1,414.1
    Fair Value    
    Derivative [Line Items]    
    Notes and bonds payable $ 1,706.7 $ 1,425.8
    XML 55 R29.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases - Lease Income (Details)
    $ in Millions
    3 Months Ended
    Mar. 31, 2020
    USD ($)
    Leases [Abstract]  
    Rental income $ 122.6
    XML 56 R25.htm IDEA: XBRL DOCUMENT v3.20.1
    Fair Value of Financial Instruments (Tables)
    3 Months Ended
    Mar. 31, 2020
    Fair Value Disclosures [Abstract]  
    Fair value and carrying values for notes and bonds payable, mortgage notes receivable, and notes receivable
    The table below details the fair values and carrying values for notes and bonds payable at March 31, 2020 and December 31, 2019.
     
    MARCH 31, 2020
    DECEMBER 31, 2019
    Dollars in millions
    CARRYING VALUE

    FAIR VALUE

    CARRYING VALUE

    FAIR VALUE

    Notes and bonds payable 1
    $
    1,644.5

    $
    1,706.7

    $
    1,414.1

    $
    1,425.8


    1
    Level 2 – model-derived valuations in which significant inputs and significant value drivers are observable in active markets.
    XML 57 R21.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases (Tables)
    3 Months Ended
    Mar. 31, 2020
    Leases [Abstract]  
    Future Minimum Lease Payments Receivable
    Future lease payments under the non-cancelable operating leases, excluding any reimbursements, as of March 31, 2020 were as follows:
    In thousands
     
    2020
    $
    280,413

    2021
    335,188

    2022
    294,771

    2023
    250,284

    2024
    193,772

    2025 and thereafter
    514,144

     
    $
    1,868,572


    Future Minimum Operating Lease Payments
    The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of March 31, 2020 were as follows:
    In thousands
    OPERATING

    FINANCING

    2020
    $
    3,113

    $
    429

    2021
    4,844

    754

    2022
    4,875

    763

    2023
    4,913

    774

    2024
    4,969

    795

    2025 and thereafter
    307,665

    83,404

    Total undiscounted lease payments
    330,379

    86,919

    Discount
    (239,286
    )
    (68,966
    )
    Lease liabilities
    $
    91,093

    $
    17,953



    Future Minimum Financing Lease Payments
    The Company’s future lease payments (primarily for its 62 non-prepaid ground leases) as of March 31, 2020 were as follows:
    In thousands
    OPERATING

    FINANCING

    2020
    $
    3,113

    $
    429

    2021
    4,844

    754

    2022
    4,875

    763

    2023
    4,913

    774

    2024
    4,969

    795

    2025 and thereafter
    307,665

    83,404

    Total undiscounted lease payments
    330,379

    86,919

    Discount
    (239,286
    )
    (68,966
    )
    Lease liabilities
    $
    91,093

    $
    17,953



    Lease Cost
    The following table provides details of the Company's total lease expense for the three months ended March 31, 2020 and 2019:
     
    THREE MONTHS ENDED MARCH 31,
    In thousands
    2020

    2019

    Operating lease cost
     
     
    Operating lease expense
    $
    1,174

    $
    1,116

    Variable lease expense
    800

    740

     
     
     
    Finance lease cost
     
     
    Amortization of right-of-use assets
    70


    Interest on lease liabilities
    237


    Total lease expense
    $
    2,281

    $
    1,856

     
     
     
    Other information
     
     
    Operating cash flows outflows related to operating leases
    $
    2,550

    $
    2,771

    Financing cash flows outflows related to financing leases
    $
    321

    $

    Right-of-use assets obtained in exchange for new finance lease liabilities
    $

    $

     
     
     
    Weighted-average remaining lease term (excluding renewal options) - operating leases
    49.4

    54.0

    Weighted-average remaining lease term (excluding renewal options) -finance leases
    64.9


    Weighted-average discount rate - operating leases
    5.7
    %
    5.5
    %
    Weighted-average discount rate - finance leases
    5.4
    %
    %

    XML 58 R17.htm IDEA: XBRL DOCUMENT v3.20.1
    Subsequent Events
    3 Months Ended
    Mar. 31, 2020
    Subsequent Events [Abstract]  
    Subsequent Events Subsequent Events
    COVID-19 Update
    Since being reported in December 2019, COVID-19 has spread globally, including to every state in the United States. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic, and on March 13, 2020, the United States declared a national emergency with respect to COVID-19.
    All of the states and cities in which the Company owns properties, manages properties, and/or has development or redevelopment projects have instituted quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of businesses that may continue to operate, and/or restrictions on the types of construction projects that may continue. As a result, a number of the Company's tenants have temporarily closed their offices or clinical space or have operated on a reduced basis in response to government requirements or recommendations. Through May 5, 2020, the Company has collected 89% of April 2020 aggregate tenant billings and has agreed to various forms of rent deferrals representing approximately 7% of April 2020 aggregate tenant billings. The tenant deferral agreements require the deferred amounts to be repaid in the third and fourth quarters of 2020. However, if tenants are unable to timely repay, or repay at all, deferred rent, if they request additional rent deferrals or abatements, decide not to renew leases, or renew leases at lower cash leasing spreads, the impact on the Company’s results of operations and financial condition could be material. Given the daily evolution of the COVID-19 pandemic and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity for the fiscal year 2020. The Company continues to evaluate the impact of various forms of governmental assistance that may be or become available to the Company or its tenants, including the Coronavirus Aid, Relief, and Economic Security Act or the “CARES Act".
    XML 59 R13.htm IDEA: XBRL DOCUMENT v3.20.1
    Derivative Financial Instruments
    3 Months Ended
    Mar. 31, 2020
    Derivative Instruments and Hedging Activities Disclosure [Abstract]  
    Derivative Financial Instruments Derivative Financial Instruments
    Risk Management Objective of Using Derivatives
    The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk, primarily by managing the amount, sources, and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company’s derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s borrowings.

    Cash Flow Hedges of Interest Rate Risk
    The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.
    For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (Loss) ("AOCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in AOCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt.
    On February 24 and 25, 2020, the Company entered into two treasury rate locks totaling $75.0 million and $40.0 million, respectively. The treasury rate locks were settled for an aggregate amount of $4.3 million on March 4, 2020 concurrent with the Company's issuance of its Senior Notes due 2030. The settlement will be amortized over the 10-year term of the notes.
    As of March 31, 2020, the Company had eight outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:
    DERIVATIVE INSTRUMENT
    NUMBER OF INSTRUMENTS

    NOTIONAL AMOUNT
    in millions
    Interest rate swaps
    8

    $175.0


    Tabular Disclosure of Fair Values of Derivative Instruments on the Balance Sheet
    The table below presents the fair value of the Company's derivative financial instruments, as well as their classification on the Condensed Consolidated Balance Sheet as of March 31, 2020.
     
    BALANCE AT MARCH 31, 2020
    In thousands
    BALANCE SHEET LOCATION
    FAIR VALUE

    Derivatives designated as hedging instruments
     
     
    Interest rate swaps
    Other liabilities
    $
    14,672

    Total derivatives designated as hedging instruments
     
    $
    14,672



    Tabular Disclosure of the Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss)
    The table below presents the effect of cash flow hedge accounting on AOCI during the three months ended March 31, 2020 and 2019 related to the Company's outstanding interest rate swaps.
     
    LOSS RECOGNIZED IN
    AOCI ON DERIVATIVE
    three months ended March 31,
     
    (GAIN) LOSS RECLASSIFIED FROM
    AOCI INTO INCOME
    three months ended March 31,
    In thousands
    2020

    2019

    2020

    2019

    Interest rate swaps
    $
    9,663

    $
    724

    Interest expense
    $
    271

    $
    (27
    )
    Settled treasury hedges
    4,267


    Interest expense
    15


    Settled interest rate swaps


    Interest expense
    42

    42

     
    $
    13,930

    $
    724

    Total interest expense
    $
    328

    $
    15

    The Company estimates that $4.0 million will be reclassified from AOCI to interest expense over the next 12 months.
    Credit-risk-related Contingent Features
    The Company's agreements with each of its derivative counterparties contain a cross-default provision under which the Company could be declared in default of its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.
    As of March 31, 2020, the fair value of derivatives in a net liability position including accrued interest but excluding any adjustment for nonperformance risk related to these agreements was $15.2 million. As of March 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement.
    XML 60 R2.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
    $ in Thousands
    Mar. 31, 2020
    Dec. 31, 2019
    Real estate properties    
    Land $ 319,882 $ 289,751
    Buildings, improvements and lease intangibles 4,126,046 3,986,326
    Personal property 10,783 10,538
    Construction in progress 0 48,731
    Land held for development 24,647 24,647
    Real estate properties, Total 4,481,358 4,359,993
    Less accumulated depreciation and amortization (1,164,462) (1,121,102)
    Total real estate properties, net 3,316,896 3,238,891
    Cash and cash equivalents 103,370 657
    Assets held for sale, net 20 37
    Operating lease right-of-use assets 125,040 126,177
    Financing lease right-of-use assets 12,615 12,667
    Other assets, net 189,708 185,426
    Total assets 3,747,649 3,563,855
    Liabilities    
    Notes and bonds payable 1,644,454 1,414,069
    Accounts payable and accrued liabilities 64,574 78,517
    Liabilities of properties held for sale 74 145
    Operating lease liabilities 91,093 91,574
    Financing lease liabilities 17,953 18,037
    Other liabilities 70,073 61,504
    Total liabilities 1,888,221 1,663,846
    Commitments and contingencies
    Stockholders' equity    
    Preferred stock, $.01 par value per share; 50,000 shares authorized; none issued and outstanding 0 0
    Common stock, $.01 par value per share; 300,000 shares authorized; 134,932 and 134,706 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively 1,349 1,347
    Additional paid-in capital 3,494,123 3,485,003
    Accumulated other comprehensive loss (19,777) (6,175)
    Cumulative net income attributable to common stockholders 1,131,619 1,127,304
    Cumulative dividends (2,747,886) (2,707,470)
    Total stockholders' equity 1,859,428 1,900,009
    Total liabilities and stockholders' equity $ 3,747,649 $ 3,563,855
    XML 61 R30.htm IDEA: XBRL DOCUMENT v3.20.1
    Leases - Lessor Accounting (Details)
    $ in Thousands
    Mar. 31, 2020
    USD ($)
    Future Lease Payments Receivable [Abstract]  
    2020 $ 280,413
    2021 335,188
    2022 294,771
    2023 250,284
    2024 193,772
    2025 and thereafter 514,144
    Total $ 1,868,572
    XML 62 R6.htm IDEA: XBRL DOCUMENT v3.20.1
    Condensed Consolidated Statements of Equity (Unaudited) Statement - USD ($)
    $ in Thousands
    Total
    Common Stock
    Additional Paid-In Capital
    Accumulated Other Comprehensive Income (Loss)
    Cumulative Net Income
    Cumulative Dividends
    Beginning balance at Dec. 31, 2018 $ 1,716,642 $ 1,253 $ 3,180,284 $ (902) $ 1,088,119 $ (2,552,112)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock, net of issuance costs 120,500 38 120,462      
    Common stock redemptions (570)   (570)      
    Share-based compensation 2,639 1 2,638      
    Net income 4,891       4,891  
    Reclassification adjustments for losses included in net income (interest expense) 15     15    
    Losses arising during the period on interest rate swaps (724)     (724)    
    Dividends to common stockholders (37,614)         (37,614)
    Ending balance at Mar. 31, 2019 1,805,779 1,292 3,302,814 (1,611) 1,093,010 (2,589,726)
    Beginning balance at Dec. 31, 2019 1,900,009 1,347 3,485,003 (6,175) 1,127,304 (2,707,470)
    Increase (Decrease) in Stockholders' Equity [Roll Forward]            
    Issuance of common stock, net of issuance costs 7,321 2 7,319      
    Common stock redemptions (798)   (798)      
    Share-based compensation 2,599   2,599      
    Net income 4,315       4,315  
    Reclassification adjustments for losses included in net income (interest expense) 328     328    
    Losses arising during the period on interest rate swaps (13,930)     (13,930)    
    Dividends to common stockholders (40,416)         (40,416)
    Ending balance at Mar. 31, 2020 $ 1,859,428 $ 1,349 $ 3,494,123 $ (19,777) $ 1,131,619 $ (2,747,886)
    XML 63 R34.htm IDEA: XBRL DOCUMENT v3.20.1
    Notes and Bonds Payable (Details)
    3 Months Ended
    Mar. 04, 2020
    USD ($)
    derivative
    Feb. 03, 2020
    USD ($)
    ft²
    Mar. 31, 2020
    USD ($)
    ft²
    Feb. 25, 2020
    USD ($)
    Feb. 24, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 1,644,454,000     $ 1,414,069,000
    Area of real estate property | ft²     15,800,000      
    Line of Credit | $700 million Unsecured Credit Facility            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 215,000,000     293,000,000
    Effective interest rate     1.89%      
    Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 199,069,000     199,013,000
    Effective interest rate     3.20%      
    Medium-term Notes | $150 million Unsecured Term Loan due 2026            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 0     0
    Term-loan facility     150,000,000.0      
    Senior Notes | Senior Notes due 2023, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 248,647,000     248,540,000
    Effective interest rate     3.95%      
    Senior Notes | Senior Notes due 2025, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 248,584,000     248,522,000
    Effective interest rate     4.08%      
    Senior Notes | Senior Notes due 2028, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 295,768,000     295,651,000
    Effective interest rate     3.84%      
    Senior Notes | Senior Notes due 2030, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Fixed interest rate 2.40%          
    Notes and bonds payable     $ 296,211,000     0
    Term-loan facility $ 300,000,000.0          
    Effective interest rate 2.71%   2.71%      
    Debt issuance costs $ 2,800,000          
    Debt discount $ 1,000,000.0          
    Number of Derivative Instruments Settled | derivative 2          
    Mortgages | Mortgage notes payable, net of discounts and issuance costs and including premiums            
    Debt Instrument [Line Items]            
    Notes and bonds payable     $ 141,175,000     $ 129,343,000
    Effective interest rate     4.70%      
    Interest Rate Swap | Medium-term Notes | $200 million Unsecured Term Loan Facility, net of issuance costs            
    Debt Instrument [Line Items]            
    Notional amount     $ 175,000,000.0      
    Fixed interest rate     2.29%      
    Debt Instrument, Basis Spread on Variable Rate     100.00%      
    Interest Rate Swap | Senior Notes | Senior Notes due 2025, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Loss on derivative instrument agreement recognized in OCI     $ 1,700,000      
    Treasury Lock            
    Debt Instrument [Line Items]            
    Notional amount       $ 40,000,000.0 $ 75,000,000.0  
    Loss on derivative instrument agreement recognized in OCI $ 4,300,000          
    Treasury Lock | Senior Notes | Senior Notes due 2025, net of discount and issuance costs            
    Debt Instrument [Line Items]            
    Loss on derivative instrument agreement recognized in OCI $ 4,300,000   $ 4,300,000      
    Mortgages            
    Debt Instrument [Line Items]            
    Fixed interest rate   6.10%        
    Outstanding principal repaid   $ 5,900,000        
    Area of real estate property | ft²   68,860        
    XML 64 R38.htm IDEA: XBRL DOCUMENT v3.20.1
    Commitments and Contingencies - Construction Activity (Details)
    $ in Millions
    3 Months Ended
    Mar. 31, 2020
    USD ($)
    ft²
    Other Commitments [Line Items]  
    Approximate Square Feet | ft² 15,800,000
    Medical Office Building Expansion | Memphis, Tennessee  
    Other Commitments [Line Items]  
    Approximate Square Feet | ft² 110,883
    Medical Office Building | Memphis, Tennessee  
    Other Commitments [Line Items]  
    Construction Activity, Total Funding During the Period, Excluding Purchase of Land and Building $ 1.5
    Medical Office Building | Washington  
    Other Commitments [Line Items]  
    Approximate Square Feet | ft² 151,031
    Total amount funded $ 54.1
    Estimated amount to complete project 10.0
    Land and Building | Medical Office Building | Memphis, Tennessee  
    Other Commitments [Line Items]  
    Construction Activity, Total Funding During the Period $ 8.7

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